101 results on '"Sablot D"'
Search Results
2. Tenecteplase in acute ischemic stroke: Review of the literature and expert consensus from the French Neurovascular Society
- Author
-
Olindo, S., Albucher, J.-F., Bejot, Y., Berge, J., Cordonnier, C., Guillon, B., Sablot, D., Tardy, J., Alamowitch, S., and Sibon, I.
- Published
- 2023
- Full Text
- View/download PDF
3. Results of a 1-year quality-improvement process to reduce door-to-needle time in acute ischemic stroke with MRI screening
- Author
-
Sablot, D., Gaillard, N., Colas, C., Smadja, P., Gely, C., Dutray, A., Bonnec, J.-M., Jurici, S., Farouil, G., Ferraro-Allou, A., Jantac, M., Allou, T., Pujol, C., Olivier, N., Laverdure, A., Fadat, B., Mas, J., Dumitrana, A., Garcia, Y., Touzani, H., Perucho, P., Moulin, T., Richard, C., Heroum, C., Bouly, S., Sagnes-Raffy, C., and Heve, D.
- Published
- 2017
- Full Text
- View/download PDF
4. Intérêt d'un transport infirmier interhospitalier pour traitement endovasculaire dans un centre de recours avec neuroradiologie interventionnelle.
- Author
-
Jebali, C., Leibinger, F., Jebali, N., Utges, R., Ortega, L., and Sablot, D.
- Subjects
NIH Stroke Scale ,HEALTH services accessibility ,BASILAR artery ,SCIENTIFIC observation ,MOBILE hospitals ,FUNCTIONAL status ,EMERGENCY medical services ,RESUSCITATION ,DESCRIPTIVE statistics ,LONGITUDINAL method ,ISCHEMIC stroke ,ATRIAL fibrillation ,THROMBECTOMY ,HEALTH facilities ,REPERFUSION ,PHYSICIANS ,TRANSPORTATION of patients ,MEDICAL referrals ,DISEASE complications - Abstract
Copyright of Annales Françaises de Médecine d'Urgence is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
5. Is off-label thrombolysis safe and effective in a real-life primary stroke center? A retrospective analysis of data from a 5-year prospective database
- Author
-
Sablot, D., primary, Leibinger, F., additional, Dutray, A., additional, Van Damme, L., additional, Nguyen Them, L., additional, Farouil, G., additional, Jebali, C., additional, Arquizan, C., additional, Ibanez-Julia, M.-J., additional, Laverdure, A., additional, Allou, T., additional, Chaabane, W., additional, Fadat, B., additional, Olivier, N., additional, Smadja, P., additional, Tardieu, M., additional, Lachcar, M., additional, Mas, J., additional, Ousji, A., additional, Jurici, S., additional, Mourand, I., additional, Ferraro, A., additional, Dumitrana, A., additional, Bensalah, Z.M., additional, Damon, F., additional, Tincau, O.-A., additional, Valverde, D., additional, Mekue-Fotso, V., additional, Bonafe, A., additional, Ortega, L., additional, and Gaillard, N., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Hemiballism-hemichorea revealing carotidal stenosis
- Author
-
Ion, I., primary, Parvu, T., additional, Farouil, G., additional, and Sablot, D., additional
- Published
- 2022
- Full Text
- View/download PDF
7. A regional strategy to decrease the time to thrombectomy in patients with low probability of treatment by thrombolysis
- Author
-
Ter Schiphorst, A., primary, Duflos, C., additional, Mourand, I., additional, Gaillard, N., additional, Dargazanli, C., additional, Corti, L., additional, Prin, P., additional, Lippi, A., additional, Ayrignac, X., additional, Charif, M., additional, Wacongne, A., additional, Bouly, S., additional, Lalu, T., additional, Sablot, D., additional, Blanchet-Fourcade, G., additional, Landragin, N., additional, Jacob, F., additional, Sayad, C., additional, Derraz, I., additional, Cagnazzo, F., additional, Lefevre, P.-H., additional, Gascou, G., additional, Beaufils, O., additional, Costalat, V., additional, and Arquizan, C., additional
- Published
- 2022
- Full Text
- View/download PDF
8. Intérêt prédictif de l’évolution des facteurs posturaux et locomoteurs après ponction lombaire soustractive dans l’hydrocéphalie chronique de l’adulte
- Author
-
Mary, P., Gallisa, J.-M., Laroque, S., Bedou, G., Maillard, A., Bousquet, C., Negre, C., Gaillard, N., Dutray, A., Fadat, B., Jurici, S., Olivier, N., Cisse, B., and Sablot, D.
- Published
- 2013
- Full Text
- View/download PDF
9. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study
- Author
-
Siri, A., Carra-Dalliere, Clarisse, Ayrignac, X., Pelletier, J., Audoin, B., Pittion-Vouyovitch, S., Debouverie, M., Lionnet, C., Viala, F., Sablot, D., Brassat, D., Ouallet, J.-C., Ruet, A., Brochet, B., Taillandier, L., Bauchet, L., Derache, N., Defer, G., Cabre, P., de Seze, J., Lebrun Frenay, C., Cohen, M., and Labauge, P.
- Published
- 2015
- Full Text
- View/download PDF
10. Endovascular treatment for acute ischemic stroke at a primary stroke center: First results of the Perpignan center
- Author
-
Sablot, D., primary, Farouil, G., additional, Leibinger, F., additional, Van Damme, L., additional, Aptel, S., additional, Fadat, B., additional, Tardieu, M., additional, Dutray, A., additional, Gascou, G., additional, Olivier, N., additional, Seiller, I., additional, Nguyen Them, L., additional, Smadja, P., additional, Ibanez-Julia, M.-J., additional, Arquizan, C., additional, Mas, J., additional, Jurici, S., additional, Dumitrana, A., additional, Ferraro, A., additional, Costalat, V., additional, and Bonafe, L., additional
- Published
- 2022
- Full Text
- View/download PDF
11. Utilisation du rt-PA intraveineux dans l’ischémie cérébrale en Centre Hospitalier Général : l’expérience de l’Hôpital Saint-Jean de Perpignan
- Author
-
Sablot, D., Cassarini, J.-F., Akouz, A., Benejean, J.-M., Leibinger, F., Faillie, X., Vidry, E., Ayrignac, X., Castro, S., Sinaya, L., Bertrand, J.-L., Garcia, Y., Arnoud, B., and Negre, C.
- Published
- 2006
- Full Text
- View/download PDF
12. Predictors of Favorable Outcome after Endovascular Thrombectomy in MRI: Selected Patients with Acute Basilar Artery Occlusion
- Author
-
Mahmoudi, M., primary, Dargazanli, C., additional, Cagnazzo, F., additional, Derraz, I., additional, Arquizan, C., additional, Wacogne, A., additional, Labreuche, J., additional, Bonafe, A., additional, Sablot, D., additional, Lefevre, P.H., additional, Gascou, G., additional, Gaillard, N., additional, Scott, C., additional, Costalat, V., additional, and Mourand, I., additional
- Published
- 2020
- Full Text
- View/download PDF
13. Angioedema associated with thrombolysis for ischemic stroke: analysis of a case‐control study
- Author
-
Vigneron, C., primary, Lécluse, A., additional, Ronzière, T., additional, Bouillet, L., additional, Boccon‐Gibod, I., additional, Gayet, S., additional, Doche, E., additional, Smadja, D., additional, Di Legge, S., additional, Dumont, F., additional, Gaudron, M., additional, Ion, I., additional, Marcel, S., additional, Sévin, M., additional, Vlaicu, M. B., additional, Launay, D., additional, Arnaud, I., additional, Girard‐Madoux, P., additional, Héroum, C., additional, Lefèvre, S., additional, Marc, G., additional, Obadia, M., additional, Sablot, D., additional, Sibon, I., additional, Suissa, L., additional, Gobert, D., additional, Detante, O., additional, Alamowitch, S., additional, Fain, O., additional, and Javaud, N., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study
- Author
-
Bousser, M, Amarenco, P, Chamorro, A, Fisher, M, Ford, I, Fox, K, Hennerici, M, Mattle, H, Rothwell, P, Julian, D, Fieschi, G, Fieschi, C, Boysen, G, Pocock, S, Conard, J, Orgogozo, J, Inzitari, D, Erkinjuntti, T, Pasquier, F, O'Brien, J, Mas, J, Gueret, P, Lenzi, G, Leys, D, Lopez Sendon, J, Norrving, B, Ferro, J, Thygesen, K, Cowpply, B, P, Ameriso, S, Donnan, D, Lang, W, Thijs, V, Fernandes, J, Stamenova, P, Teal, P, Lavados, P, Lu, C, Poljakovic, Z, Kalita, Z, Kaste, M, Moulin, T, Vemmos, K, Diener, H, Wong, L, Nagy, Z, Chopra, J, Mccormack, P, Gensini, G, Budrys, V, Droste, D, Tan, K, Benomar, A, Cantu Brito, C, Barber, A, Koudstaal, P, Thomassen, L, Czlonkowska, A, Cunha, L, Bajenaru, O, Yakhno, N, Chen, C, Lisy, L, Zvan, B, Bryer, A, Kim, J, Vivancos, J, Wahlgren, N, Liu, S, Poungvarin, N, Hentati, F, Bahar, S, Mischenko, T, Lees, K, Abdel Masih, M, Barboza, A, Cirio, J, Crespo, E, Escaray, G, Esnaola, M, Rojas Estol, C, Ferrari, J, Fraiman, H, Garrote, M, Gatto, E, Giannaula, R, Gori, H, Herrera, G, Ioli, P, Losano, J, Povedano Reich, E, Rey, R, Rotta Escalante, R, Saredo, G, Zurru, M, Anderson, C, Bladin, C, Crimmins, D, Davis, S, Donnan, G, Dunbabin, D, Frayne, J, Gates, P, Hankey, G, Helme, R, Herkes, G, Karrasch, J, Kimber, T, Jannes, J, Landau, P, Levi, C, Lueck, C, Markus, R, Phan, T, Schwartz, R, Schultz, D, Blacker, D, Read, S, Williams, M, Aichner, F, Auff, E, Bancher, C, Binder, H, Brainin, M, Brucke, T, Eggers, C, Fertl, E, Ladurner, G, Lalouschek, W, Mamoli, B, Mitrovic, N, Noisternig, G, Schmidt, R, Vosko, M, Willeit, J, Zaruba, E, Boon, P, Bourgeois, P, Caekebeke, J, Cals, N, Cras, P, Desfontaines, P, De Deyn, P, Dieudonne, L, De Klippel, N, Laloux, P, Maertens de Noordhout, A, Merlevede, K, Michotte, A, Pandolfo, M, Peeters, A, Peeters, D, Tack, P, Van Buggenhout, E, Van Landegem, W, Vanhooren, G, Vermylen, P, Annes, M, Brondani, R, De Carvalho, J, Cendes, F, Fabio, S, Ferraz, A, De Freitas, G, Gagliardi, R, Gomes Neto, A, Haussen, S, Kowacs, P, Martins, S, Minelli, C, Moro, C, Noujaim, J, Rocha, M, Da Silva, M, Silveira, J, Yamamoto, F, Zetola, V, Baldaranov, D, Deleva, N, Haralanov, L, Milanov, I, Mintchev, D, Petrova, N, Shotekov, P, Stamenov, B, Zahariev, Z, Arts, R, Bayer, N, Beaudry, M, Berger, L, Bozek, C, Collier, T, Cote, R, Desai, H, Durocher, A, Hachinski, V, Hill, M, Hoppe, B, Howse, D, Mackey, A, Maharaj, M, Minuk, J, Moddel, G, Novak, D, Penn, A, Rabinovitch, H, Selchen, D, Shuaib, A, Silva, J, Silver, F, Spence, D, Stotts, G, Tamayo, A, Teitelbaum, J, Veloso, F, Voll, C, Winder, T, Barrientos Uribe, N, Galdames Poblete, D, Garcia Figueroa, P, Gasic Yaconi, K, Jaramillo Munoz, A, Lavados Germain, P, Lavados Montes, M, Nancupil Bello, C, Prina Pacheco, L, Vargas Canas, A, Venegas, F, Chen, P, H, Cheng, Y, Cui, L, Di, Q, Dong, Q, Fan, D, Feng, H, Huang, Y, Li, J, Li, W, Li, Z, Lin, H, Liu, M, Miao, L, Ren, H, Wang, Y, Wu, J, Zhang, W, Zhao, G, Zhao, H, Zhou, H, Antoncic, I, Demarin, V, Lusic, I, Pavlicek, I, Soldo Butkovic, S, Bar, M, Bauer, J, Kalina, M, Kanovsky, P, Jura, R, Neumann, J, Rektor, I, Skoda, O, Vaclavik, D, Eerola, A, Hillbom, M, Kinnunen, E, Koivisto, K, Numminen, H, Rissanen, A, Roine, R, Sivenius, J, Alamowitch, S, Autret, A, Avendano, S, Bataillard, M, Berthier, E, Besson, G, Bille Turc, F, Boulliat, J, Boulesteix, J, Brosset, C, Cesaro, P, Albucher, J, Clavelou, P, Colamarino, R, Crassard, I, de Broucker, T, de Bray, J, Desbordes, P, Diot, E, Ducrocq, X, Ellie, E, Faucheux, J, Giroud, M, Godefroy, O, Guillon, B, Huttin, H, Just, A, Lamy, C, Lejeune, P, Lucas, C, Macian Montoro, F, Mackowiak, A, Maillet Vioud, M, Pico, F, Milandre, L, Milhaud, D, Malbec, M, Neau, J, Pinel, J, Robin, C, Rodier, G, Rosolacci, T, Rouanet, F, Rouhart, F, Sablot, D, Servan, J, Smadja, D, Trouillas, P, Valance, J, Viader, F, Viallet, F, Wolff, V, Zagnoli, F, Zuber, M, Angerer, M, Becker, U, Berlit, P, Berrouschot, J, Biniek, R, Bitsch, A, Brodhun, R, Dichgans, M, Druschky, K, Dux, R, Faiss, J, Ferbert, A, Gahn, G, Grotemeyer, K, Goertler, M, Grau, A, Griewing, B, Grond, M, Haan, J, Haberl, R, Hamann, G, Hamer, H, Harms, L, Heide, W, Henningsen, H, Hetzel, A, Hoffmann, F, Huber, R, Isenmann, S, Jander, S, Joerg, J, Kaps, M, Kastrup, A, Kessler, C, Koehler, W, Koelmel, H, Lichy, C, Luckner, K, Malessa, R, Mallmann, A, Meyding Lamade, U, Molitor, H, Mueller Jensen, A, Muellges, W, Noth, J, Nueckel, M, Ochs, G, Poppert, H, Roether, J, Rosenkranz, M, Sander, D, Schaebitz, W, Schlachetzki, F, Schlegel, U, Schmid, E, Schneider, D, Schwarz, M, Seidel, G, Sieble, M, Sliwka, U, Stingele, R, Stoegbauer, F, Szabo, K, Topper, R, Treib, J, Weissenborn, K, Widder, B, Witte, O, Karageorgiou, K, Mitsikostas, D, Papadimitriou, A, Papathanasopoulos, P, Chan, H, Ng, P, Tsoi, T, Bartos, L, Csanyi, A, Csiba, L, Csornai, M, Dioszeghy, P, Fazekas, A, Harcos, P, Horvath, S, Kaposzta, Z, Kerenyi, L, Kincses, J, Koves, A, Nikl, J, Panczel, G, Pongracz, E, Sebestyen, K, Semjen, J, Szabo, M, Szegedi, N, Valikovics, A, Varszegi, R, Vecsei, L, Borah, N, Ichaporia, N, Kaul, S, Meenakshi Sundaram, S, Mehndiratta, M, Misra, U, Murthy, J, Nayak, D, Poncha, F, Shah, A, Singh, G, Srinivasa, R, Venkateswarlu, K, Wadia, R, Collins, R, Harbison, J, Hickey, P, Kelly, P, Murphy, S, Adami, A, Agnelli, G, Agostoni, E, Anzola, G, Arnaboldi, M, Bassi, P, Billo, G, Bottacchi, E, Bovi, P, Cappa, S, Cappelletti, C, Carolei, A, Cavallini, A, Chiodo Grandi, F, Comi, G, Consoli, D, Corsi, F, Costanzo, E, De Falco, F, Devetag, F, Di Lazzaro, V, Di Piero, V, Diomedi, M, Fattorello Salimbeni, C, Federico, F, Feleppa, M, Ferrarese, C, Gandolfo, C, Giaccaglini, E, Giaquinto, S, Giobbe, D, Giometto, B, Greco, G, Guidetti, D, Guidotti, M, Iudice, A, Lembo, G, Marengo, C, Marini, P, Melis, M, Micieli, G, Musolino, R, Mutani, R, Neri, G, Parati, E, Pastore, L, Porazzi, D, Prati, P, Procaccianti, G, Rasura, M, Rossini, P, Santilli, I, Semplicini, A, Silvestrini, M, Tanganelli, P, Tedeschi, G, Tezzon, F, Tola, M, Villani, A, Zanferrari, C, Zarcone, D, Bickuviene, I, Gumbrevicius, G, Obelieniene, D, Skaringa, A, Virketiene, I, Tharakan, J, Aleman Pedroza, J, Escamilla Garza, J, Fernandez Vera, J, Leal Cantu, R, Leon Flores, L, Lopez Ruiz, M, Reyes Gutierrez, G, Reyes Morales, S, Rivera Castano, L, Rodrigues Leyva, I, Ruiz Sandoval, J, Vega Boada, F, Belahsen, F, Kissani, N, Mosseddaq, R, Slassi, I, Yahyaoui, M, Boiten, J, Bornebroek, M, De Kort, P, De Leeuw, H, Donders, R, Franke, C, Hertzberger, L, Jansen, B, Kappelle, L, Keizer, K, Kuster, J, Limburg, M, Mulleners, W, Pop, P, Van Den Berg, J, Van Gemert, H, Verbiest, H, Weinstein, H, Clark, M, Fink, J, Gommans, J, Jayathissa, S, Kilfoyle, D, Kumar, A, Hurtig, U, Indredavik, B, Kloster, R, Salvesen, R, Drozdowski, W, Fryze, W, Klimek, A, Kochanowski, J, Kozubski, W, Ksiazkiewicz, B, Kwiecinski, H, Kuczynska Zardzewialy, A, Motta, E, Nowacki, P, Nyka, W, Opala, G, Pierzchala, K, Pniewski, J, Podemski, R, Selmaj, K, Stelmasiak, Z, Stepien, A, Strzelecka Gorzynska, M, Szczudlik, A, Wajgt, A, Wiszniewska, M, Wlodek, A, Canhao, P, Correia, C, Grilo Goncalves, J, Machado Candido, J, Salgado, A, Bulboaca, A, Campeanu, A, Lazar, T, Marginean, I, Minea, D, Pascu, I, Pereanu, M, Perju Dumbrava, L, Popescu, C, Simu, M, Stefanache, F, Toldisan, I, Tuta, S, Zaharia, C, Alifirova, V, Arkhipov, S, Balunov, O, Balyazin, V, Belkin, A, Belova, A, Boiko, A, Bogdanov, E, Butko, D, Chukhlovina, M, Doronin, B, Ermilova, E, Evzelman, M, Fedin, A, Fedorova, N, Golikov, K, Golovkin, V, Gusev, E, Gustov, A, Jakupov, E, Kamchatnov, P, Khabirov, F, Kirienko, A, Klimov, I, Klocheva, E, Kotov, S, Kuznetsov, A, Laskov, V, Levin, Y, Mashkova, N, Nazarov, A, Novikova, L, Odinak, M, Parfenov, V, Pilipenko, P, Pokrovsky, A, Poverennova, I, Rodoman, G, Roshkovskaya, L, Shirokov, E, Shmyriov, V, Sholomov, I, Skoromets, A, Skvortsova, V, Spirin, N, Stakhovskaya, L, Sharov, M, Sherman, M, Shutov, A, Strachunskaya, E, Stulin, I, Suslina, Z, Volosevitch, A, Vorobiev, P, Vorobyeva, O, Voronkova, L, Voskresenskaya, O, Zhuliov, N, Chan, B, Chang, H, Ramani, N, Brozman, M, Dvorak, M, Dzugan, J, Garay, R, Gdovinova, Z, Gurcik, L, Krastev, G, Kukumberg, P, Kurca, E, Meluch, S, Nyeky, M, Turcani, P, Vyletelka, J, Klanjscek, G, Zujovic, E, Zupan, M, Bester, F, Carr, J, Coetzee, C, Frost, A, Gardiner, J, Giampaolo, D, Kesler, S, Lurie, D, Retief, C, Roos, J, Bae, H, Cha, J, Cho, K, Heo, J, Kim, E, Lee, B, Lee, K, Lee, J, Rha, J, Yoon, B, Alvarez Sabin, J, Arboix Damunt, A, De Arce Borda, A, Asensi Alvarez JM, Bermejo Pareja, F, Botia Paniagua, E, Casado, I, Naranjo, I, Castillo Sanchez, J, Chamorro Sanchez, A, Davalos Errando, A, Diaz Marin, C, Diez Tejedor, E, Egido Herrero JA, Fernandez Bolanos, R, Fernandez Fernandez, O, Figuerola Roig, A, Geffner Sclarsky, D, Gil Nunez, A, Gomez Sanchez JC, Gomez Escalonilla Escobar CI, Gonzalez Masegosa, A, Gonzalez Menacho, J, Gracia Fleta, F, Izquierdo Ayuso, G, Jimenez Hernandez, D, Jimenez Martinez, C, Lago Martin, A, Lainez Andres JM, Larracoechea Jausoro, J, Lopez Fernandez JC, Maestre Moreno, J, Marti Vilalta JL, Martin Gonzalez, R, Masjuan Vallejo, J, Medina Rodriguez, A, Molto Jorda JM, Moreno Carre tero MJ, Moris de le Tassa, G, Morlan Gracia, L, Mostacero Miguez, E, Osuna Pulido, T, Pareja Martinez, A, Pinedo Brochado, A, Pons Amate JM, Rodriguez Alvarez JR, Roquer Gonzalez, J, Sanahuja Montesinos, J, Sanchez Sanchez MC, Segura Martin, T, Serena Leal, J, Tejada Garcia, J, Trejo Gabriel JM, Vivancos Mora, J, Andersson, B, Bysell, S, Cederin, B, Laska, A, Lindgren, A, Petersson, T, Wallen, T, Baumgartner, R, Beer, H, Hirt, L, Hungerbuehler, H, Lyrer, P, Michel, P, Mueller, F, Tettenborn, B, Chang, K, Jeng, J, Lien, L, Lin, R, Liu, C, Po, H, Wu, S, Chankrachang, S, Laptikultham, S, Nidhinandana, S, Pongpakdee, S, Benammou, S, Frih Ayed, M, Gouider, R, Mhiri, C, M'Rabet, A, Mrissa, R, Balkan, S, Can, U, Dalkara, T, Kirbas, D, Kumral, E, Ozdemir, G, Ozeren, A, Ozmenoglu, M, Ozturk, S, Lebedynets, V, Maly, V, Moskovko, S, Orzheshkovskyy, V, Smolanka, V, Yavors'Ka, V, Zozulya, I, Bamford, J, Barber, M, Barer, D, Baron, J, Bath, P, Broughton, D, Brown, M, Chataway, J, Curless, R, Darawil, K, Datta, P, Dennis, M, Durairaj, R, Egbuji, J, Ellis, S, Ford, G, Freeman, A, Fulcher, R, Gray, C, Harrington, F, Hudson, C, Iveson, E, James, M, Jenkinson, D, Kalra, L, Kelly, D, Krishnamoorthy, S, Langhorne, P, Magorrian, M, Macleod, M, Macwalter, R, Markus, H, Muhiddin, K, Muir, K, Murphy, P, Power, M, Price, C, Rashed, K, Robinson, T, Rudd, A, Sanmuganathan, P, Sharma, J, Shaw, L, Shetty, H, Smithard, D, Tyrrell, P, Vahidassr, M, Venables, G, Watt, M, White, R, Bousser, M, Amarenco, P, Chamorro, A, Fisher, M, Ford, I, Fox, K, Hennerici, M, Mattle, H, Rothwell, P, Ferrarese, C, PERFORM study, I, PERFORM STUDY, Investigator, Tedeschi, Gioacchino, Cras, Patrick, De Deyn, Peter Paul, and et al.
- Subjects
perform study ,Male ,Thromboxane ,International Cooperation ,Receptors, Thromboxane ,antiplatelet therapy ,terutroban ,Cardiovascular Disease ,Receptors ,80 and over ,Stroke ,Aged, 80 and over ,Aspirin ,Ischemic Attack ,Transient ,Ischemic Attack, Transient ,Double-Blind Method ,Endpoint Determination ,Dose-Response Relationship, Drug ,Humans ,Aged ,Propionates ,Naphthalenes ,Treatment Outcome ,Platelet Aggregation Inhibitors ,Cardiovascular Diseases ,Middle Aged ,Female ,Propionic Acids ,Neurology ,Terutroban ,Anesthesia ,tp receptor antagonist ,stroke ,secondary prevention ,aspirin ,Cardiology ,Platelet aggregation inhibitor ,Settore MED/26 - Neurologia ,stroke prevention ,Drug ,Cardiology and Cardiovascular Medicine ,medicine.drug ,Human ,medicine.medical_specialty ,Dose-Response Relationship ,Internal medicine ,medicine ,Dementia ,In patient ,business.industry ,Platelet Aggregation Inhibitor ,schemic ,medicine.disease ,DementiaI ,transient ischemic attack ,Ischemic stroke ,Human medicine ,Neurology (clinical) ,business ,Propionic Acid ,Naphthalene - Abstract
Background: Ischemic stroke is the leading cause of mortality worldwide and a major contributor to neurological disability and dementia. Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke. This article describes the rationale and design of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic Attack (PERFORM) Study, which aims to demonstrate the superiority of the efficacy of terutroban versus aspirin in secondary prevention of cerebrovascular and cardiovascular events. Methods and Results: The PERFORM Study is a multicenter, randomized, double-blind, parallel-group study being carried out in 802 centers in 46 countries. The study population includes patients aged ≥55 years, having suffered an ischemic stroke (≤3 months) or a transient ischemic attack (≤8 days). Participants are randomly allocated to terutroban (30 mg/day) or aspirin (100 mg/day). The primary efficacy endpoint is a composite of ischemic stroke (fatal or nonfatal), myocardial infarction (fatal or nonfatal), or other vascular death (excluding hemorrhagic death of any origin). Safety is being evaluated by assessing hemorrhagic events. Follow-up is expected to last for 2–4 years. Assuming a relative risk reduction of 13%, the expected number of primary events is 2,340. To obtain statistical power of 90%, this requires inclusion of at least 18,000 patients in this event-driven trial. The first patient was randomized in February 2006. Conclusions: The PERFORM Study will explore the benefits and safety of terutroban in secondary cardiovascular prevention after a cerebral ischemic event.
- Published
- 2009
15. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
- Author
-
Hacke, Werner, Kaste, Markku, Bluhmki, Erich, Brozman, Miroslav, Dávalos, Antoni, Guidetti, Donata, Larrue, Vincent, Lees, Kennedy R., Medeghri, Zakaria, Machnig, Thomas, Schneider, Dietmar, Von Kummer, Rüdiger, Wahlgren, Nils, Toni, Danilo, Hacke, W, Dávalos, A, Kaste, M, von Kummer, R, Larrue, V, Toni, D, Wahlgren, N, Lees, Kr, Heiss, Wd, Lesaffre, E, Orgogozo, Jm, Bastianello, S, Wardlaw, Jm, Peyrieux, Jc, Sauce, C, Medeghri, Z, Mazenc, R, Machnig, T, Bluhmki, E, Aichner, F, Alf, C, Baumhackl, U, Brainin, M, Eggers, C, Gruber, F, Ladurner, G, Niederkorn, K, Noistering, G, Willeit, J, Vanhooren, G, Blecic, S, Bruneel, B, Caekebeke, J, Laloux, P, Simons, Pj, Thijs, V, Bar, M, Dvorakova, H, Vaclavik, D, Boysen, G, Andersen, G, Iversen, Hk, Traberg-Kristensen, B, Marttila, R, Sivenius, J, Trouillas, P, Amarenco, P, Bouillat, J, Ducrocq, X, Giroud, M, Jaillard, A, Larrieu, Jm, Leys, D, Magne, C, Mahagne, Mh, Milhaud, D, Sablot, D, Saudeau, D, Busse, O, Berrouschot, J, Faiss, Jh, Glahn, J, Görtler, M, Grau, A, Grond, M, Haberl, R, Hamann, G, Hennerici, M, Koch, H, Krauseneck, P, Marx, J, Meves, S, Meyding-Lamadé, U, Ringleb, P, Schneider, D, Schwarz, A, Sobesky, J, Urban, P, Karageorgiou, K, Komnos, A, Csányi, A, Csiba, L, Valikovics, A, Agnelli, G, Billo, G, Bovi, P, Comi, G, Gigli, G, Guidetti, D, Inzitari, D, Marcello, N, Marini, C, Orlandi, G, Pratesi, M, Rasura, M, Semplicini, A, Serrati, C, Tassinari, T, Brouwers, Pj, Stam, J, Naess, H, Indredavik, B, Kloster, R, Czlonkowska, A, Kuczyńska-Zardzewialy, A, Nyka, W, Opala, G, Romanowicz, S, Cunha, L, Correia, C, Cruz, V, Pinho e Melo, T, Brozman, M, Dvorak, M, Garay, R, Krastev, G, Kurca, E, Alvarez-Sabin, J, Chamorro, A, del Mar Freijo Guerrero, M, Herrero, Ja, Gil-Peralta, A, Leira, R, Martí-Vilalta, Jl, Masjuan Vallejo, J, Millán, M, Molina, C, Mostacero, E, Segura, T, Serena, J, Vivancos Mora, J, Danielsson, E, Cederin, B, Von, Zweigberg, Wahlgren, Ng, Welin, L, Lyrer, P, Bogousslavsky, J, Hungerbühler, Hj, Weder, B, Ford, Ga, Jenkinson, D, Macleod, Mj, Macwalter, Rs, Markus, Hs, Muir, Kw, Sharma, Ak, Walters, Mr, Warburton, Ea, ACS - Amsterdam Cardiovascular Sciences, ANS - Amsterdam Neuroscience, and Neurology
- Subjects
Adult ,Male ,Time Factors ,medicine.medical_treatment ,Placebo ,Drug Administration Schedule ,Brain Ischemia ,Brain ischemia ,Double-Blind Method ,Fibrinolytic Agents ,Modified Rankin Scale ,medicine ,Odds Ratio ,Desmoteplase ,Humans ,Infusions, Intravenous ,Stroke ,Aged ,business.industry ,Cerebral infarction ,Medicine (all) ,General Medicine ,Thrombolysis ,Middle Aged ,medicine.disease ,Logistic Models ,Treatment Outcome ,Anesthesia ,Tissue Plasminogen Activator ,Acute Disease ,Female ,business ,Intracranial Hemorrhages ,Fibrinolytic agent - Abstract
Background Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke. Methods After exclusion of patients with a brain hemorrhage or major infarction, as detected on a computed tomographic scan, we randomly assigned patients with acute ischemic stroke in a 1:1 double-blind fashion to receive treatment with intravenous alteplase (0.9 mg per kilogram of body weight) or placebo. The primary end point was disability at 90 days, dichotomized as a favorable outcome (a score of 0 or 1 on the modified Rankin scale, which has a range of 0 to 6, with 0 indicating no symptoms at all and 6 indicating death) or an unfavorable outcome (a score of 2 to 6 on the modified Rankin scale). The secondary end point was a global outcome analysis of four neurologic and disability scores combined. Safety end points included death, symptomatic intracranial hemorrhage, and other serious adverse events. Results We enrolled a total of 821 patients in the study and randomly assigned 418 to the alteplase group and 403 to the placebo group. The median time for the administration of alteplase was 3 hours 59 minutes. More patients had a favorable outcome with alte plase than with placebo (52.4% vs. 45.2%; odds ratio, 1.34; 95% confidence interval [CI], 1.02 to 1.76; P = 0.04). In the global analysis, the outcome was also improved with alteplase as compared with placebo (odds ratio, 1.28; 95% CI, 1.00 to 1.65; P
- Published
- 2008
16. Angioplastie-stenting transluminale percutanée après dissection des troncs supra-aortiques
- Author
-
Cerutti, D., Bonafe, A., Pelouze, G.-A., Kassem, Z., Filipov, R., Runavot, G., Cassarini, J.-F., and Sablot, D.
- Published
- 2010
- Full Text
- View/download PDF
17. Les enjeux de la démographie en neurologie : résultat d’une enquête sur l’offre de soins de consultations de neurologie générale en Languedoc-Roussillon
- Author
-
Bailbe, M., primary, Geny, C., additional, and Sablot, D., additional
- Published
- 2013
- Full Text
- View/download PDF
18. Apport de l’IRM multimodale et facteurs prédictifs pour le diagnostic d’accident vasculaire cérébral ischémique lors d’un vertige aigu isolé au service d’accueil des urgences : étude prospective monocentrique au CH de Perpignan
- Author
-
Gaillard, N., primary, Dutray, A., additional, Gresillon, N., additional, Olivier, N., additional, Akouz, A., additional, Bertrand, J.-L., additional, and Sablot, D., additional
- Published
- 2013
- Full Text
- View/download PDF
19. Accès aux consultations de neurologie générale en Languedoc-Roussillon : que font les neurologues en centre hospitalier général ?
- Author
-
Sablot, D., primary
- Published
- 2013
- Full Text
- View/download PDF
20. Rituximab, traitement de la myasthénie grave : cas pratique au centre hospitalier de Perpignan
- Author
-
Quintard, A., primary, Wawrzyniak, M., additional, Sablot, D., additional, and Duplissy, E., additional
- Published
- 2012
- Full Text
- View/download PDF
21. Un PRES imprévisible
- Author
-
Laverdure, A., primary, Cartry, O., additional, Sablot, D., additional, and Cros, H., additional
- Published
- 2007
- Full Text
- View/download PDF
22. Status epilepticus in stroke: Report on a hospital-based stroke cohort
- Author
-
Rumbach, L., primary, Sablot, D., additional, Berger, E., additional, Tatu, L., additional, Vuillier, F., additional, and Moulin, T., additional
- Published
- 2000
- Full Text
- View/download PDF
23. Introduction
- Author
-
Bousquet, J., Bourret, R., Camuzat, T., Augé, P., Domy, P., Bringer, J., Best, N., Jonquet, O., de la Coussaye, J.-E., Noguès, M., Robine, J.-M., Avignon, A., Blain, H., Combe, B., Dray, G., Dufour, V., Fouletier, M., Giraudeau, N., Hève, D., Jeandel, C., Laffont, I., Larrey, D., Laune, D., Laurent, C., Mares, P., Marion, C., Pastor, E., Pélissier, J.-Y., Radier-Pontal, F., Reynes, J., Royère, E., Ychou, M., Bedbrook, A., Granier, S., Abecassis, F., Albert, S., Adnet, P.-A., Alomène, B., Amouyal, M., Arnavielhe, S., Asteriou, T., Attalin, V., Aubas, P., Azevedo, C., Badin, M., Bakhti, Baptista, G., Bardy, B., Battesti, M.-P., Bénézet, O., Bernard, P.-L., Berr, C., Berthe, J., Bobia, X., Bockaert, J., Boegner, C., Boichot, S., Bonnin, H.-Y., Boulet, P., Bouly, S., Boubakri, C., Bourdin, A., Bourrain, J.-L., Bourrel, G., Bouix, V., Breuker, C., Bruguière, V., Burille, J., Cade, S., Caimmi, D., Calmels, M.-V., Camu, W., Canovas, G., Carre, V., Cavalli, G., Cayla, G., Chiron, R., Claret, P.-G., Coignard, P., Coroian, F., Costa, D.-J., Costa, P., Cottalorda, Coulet, B., Coupet, A.-L., Courrouy-Michel, M.-C., Courtet, P., Cristol, J.-P., Cros, V., Cuisinier, F., Daien, C., Danko, M., Dauenhauer, P., Dauzat, M., David, M., Davy, J.-M., Delignières, D., Demoly, P., Desplan, J., Dhivert-Donnadieu, H., Dujols, P., Dupeyron, A., Dupeyron, G., Engberink, O., Enjalbert, M., Fattal, C., Fernandes, J., Fesler, P., Fraisse, P., Froger, J., Gabrion, P., Galano, E., Gellerat-Rogier, M., Gellis, A., Goucham, A.-Y., Gouzi, F., Gressard, F., Gris, J.-C., Guillot, B., Guiraud, D., Handweiler, V., Hantkié, H., Hayot, M., Hérisson, C., Heroum, C., Hoa, D., Jacquemin, S., Jaber, S., Jakovenko, D., Jorgensen, C., Journot, L., Kaczorek, M., Kouyoudjian, P., Labauge, P., Landreau, L., Lapierre, M., Leblond, C., Léglise, M.-S., Lemaitre, J.-M., Le Moing, V., Le Quellec, A., Leclercq, F., Lehmann, S., Lognos, B., Lussert, J.-M., Makinson, A., Mandrick, K., Marmelat, V., Martin-Gousset, P., Matheron, A., Mathieu, G., Meissonnier, M., Mercier, G., Messner, P., Meunier, C., Mondain, M., Morales, R., Morel, J., Morquin, D., Mottet, D., Nérin, P., Nicolas, P., Ninot, G., Nouvel, F., Ortiz, J.-P., Paccard, D., Pandraud, G., Pasdelou, M.-P., Pasquié, J.-L., Patte, K., Perrey, S., Pers, Y.-M., Picot, M.-C., Pin, J.-P., Pinto, N., Porte, E., Portejoie, F., Pujol, J.-L., Quantin, X., Quéré, I., Raffort, N., Ramdani, S., Ribstein, J., Rédini-Martinez, I., Richard, S., Ritchie, K., Riso, J.-P., Rivier, F., Rolland, C., Roubille, F., Sablot, D., Savy, J.-L., Schifano, L., Senesse, P., Sicard, R., Soua, B., Stephan, Y., Strubel, D., Sultan, A., Taddei-Ologeanu, Tallon, G., Tanfin, M., Tassery, H., Tavares, I., Torre, K., Touchon, J., Tribout, V., Uziel, A., Van de Perre, P., Vasquez, X., Verdier, J.-M., Vergne-Richard, C., Vergotte, G., Vian, L., Viarouge-Reunier, C., Vialla, F., Viart, F., Villain, M., Villiet, M., Viollet, E., Wojtusciszyn, A., Aoustin, M., Bourquin, C., and Mercier, J.
- Published
- 2015
- Full Text
- View/download PDF
24. Non-Valvular Atrial Fibrillation, Anticoagulants and Stroke: The Stroke Prevention and Anticoagulants (SPA) Case-Control Study
- Author
-
Grimaldi-Bensouda, L., Le Heuzey, J. -Y, Ferrieres, J., Leys, D., Davy, J. -M, Martinez, M., Smadja, D., Ellie, E., Sablot, D., Nighoghossian, N., Benichou, J., Emmanuel Touzé, and Abenhaim, L.
25. [Emergency neurology consultations in the university hospital setting: contribution of the neurologist to inpatient management]
- Author
-
thierry Moulin, Berger, E., Lemounaud, P., Vuillier, F., Tatu, L., Sablot, D., Tabailloux, D., Revenco, E., Vidry, E., Neidhardt, A., and Rumbach, L.
- Subjects
Male ,Neurologic Examination ,Inpatients ,Consultants ,Unconsciousness ,Middle Aged ,Hospitals, University ,Stroke ,Status Epilepticus ,Outpatients ,Humans ,False Positive Reactions ,Female ,France ,Emergencies ,Emergency Service, Hospital ,False Negative Reactions - Abstract
While outpatient management for chronic neurological diseases is well-established, the impact of inpatient neurological examination in emergency room and university hospital remain largely underestimated. We prospectively studied the role of the neurologist in patient management, in a primary care university hospital. Over a period of 12 months, we prospectively recorded the demographics of patients requiring examination in the emergency room, the initial suspected neurological diagnosis of the emergency room, the final diagnosis of the neurology team, and the patients' outcomes. For each patient, the time between admission, the call and the neurological examination were recorded. Neurological examinations were performed in 2220 patients in whom 75.6 p.100 were performed in the emergency room. These latter patients corresponded to 14 p.100 of all patients admitted in the emergency room. Of examined patients, 52 p.100 were male and mean age was 56.9 +/- 21 years. The time between admission and examination was 32 min. (+/- 36 min), irrespective of the day of the week, and depended on the suspected diagnosis: shorter in stroke and status epilepticus (p0.05), and longer in loss of consciousness and vertigo (p0.01). Forty-four percent of the examinations took place in the evening and night. The reasons for examinations were: stroke (28.3 p.100), epilepsy (17.7 p.100), headaches (8.4 p.100), loss of consciousness (7.9 p.100), cognitive dysfunctions (4.1 p.100), neuropathies (4 p.100) and miscellaneous (8.1 p.100). Neurological examinations modified neurological diagnosis and treatment in more than 86 p.100 of the patients. Following neurological examination, 17.2 p.100 of the patients were able to go home, while the rest were admitted to the stroke unit (27.2 p.100), the general neurological unit (27.3 p.100) or in other departments (28.3 p.100), of which intensive care unit (5.3 p.100) or neurosurgery (5.9 p.100). Emergency neurologic examination improves neurological diagnosis and has a positive impact both on treatment and, more globally, in patient management.
26. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
- Author
-
Mas, J.-L., Derumeaux, G., Guillon, B., Massardier, E., Hosseini, H., Mechtouff, L., Arquizan, C., Béjot, Y., Vuillier, F., Detante, O., Guidoux, C., Canaple, S., Vaduva, C., Dequatre-Ponchelle, N., Sibon, I., Garnier, P., Ferrier, A., Timsit, S., Robinet-Borgomano, E., and Sablot, D.
- Subjects
- *
STROKE patients , *STROKE prevention , *PLATELET aggregation inhibitors , *DRUG therapy , *HEALTH outcome assessment - Abstract
BACKGROUND Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy. METHODS In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3. RESULTS A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 238 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet-only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P<0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P = 0.02). The number of serious adverse events did not differ significantly between the treatment groups (P = 0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone. CONCLUSIONS Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE ClinicalTrials.gov number, NCT00562289.) [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Management of patients with diffusion-weighted imaging-negative acute ischemic stroke: Retrospective analysis of 47 consecutive patients.
- Author
-
Mekue Fotso V, Leibinger F, Rivas Lamelo S, Azaïs B, Plantard C, Farouil G, Fadat B, Mahmoudi M, Olivier N, Mas J, Fryder I, Balde AA, Tardieu M, Ekue W, Seiller I, Dumitrana A, Utges R, Schmidt J, Ortega L, Mesmoudi A, Van Damme L, and Sablot D
- Subjects
- Humans, Retrospective Studies, Male, Female, Aged, Middle Aged, Aged, 80 and over, Treatment Outcome, Time Factors, Disability Evaluation, Diffusion Magnetic Resonance Imaging, Ischemic Stroke diagnostic imaging, Ischemic Stroke therapy, Thrombolytic Therapy adverse effects, Endovascular Procedures adverse effects, Predictive Value of Tests, Fibrinolytic Agents administration & dosage, Fibrinolytic Agents adverse effects
- Abstract
Background: Few studies with a limited number of patients focused on the outcomes of patients with diffusion-weighted imaging (DWI)-negative acute ischemic stroke (AIS) after intravenous thrombolysis (IVT) and/or endovascular treatment (EVT)., Methods: This retrospective observational, single-center study included all consecutive patients admitted for AIS involving the anterior circulation and treated with IVT and/or EVT between January 1, 2015 and December 31, 2023. The collected data were used to identify the characteristics of patients with negative DWI and to compare outcomes in patients with negative and positive DWI., Results: Among the 1210 patients included, 47 (3.9 %) had negative (DWI-negative group) and 1163 had increased DWI signal (DWI-positive group). In the DWI-negative group, the mean age was 69 years (SD=19.4), 55.3 % were men, and 27 (57.4 %) had a large vessel occlusion. Thirty eight (80.9 %) were treated with IVT alone, 7 (14.9 %) with EVT alone, and 2 (4.3 %) with both. Fluid attenuated inversion recovery (FLAIR) sequences were the most sensitive to detect predictive factors of cerebral ischemia, such as vessel thrombosis and the spaghetti sign that were found in 68.1 % and 83 %, of patients, respectively. Oxyhemoglobin-sensitive (T2*) and susceptibility-weighted angiography (SWAN) sequences were less sensitive: vessel thrombosis and the brush sign were detected in 55.3 % and 19.1 % of patients, respectively. Comparison of the two DWI groups showed that M2 occlusion was more frequent (31.9 % vs 13 %, p<0.001) and M1 occlusion rarer (19.1 % vs 36 %, p<0.02) in the DWI-negative than DWI-positive group. At admission, the median National Institutes of Health Stroke Scale score was lower in the DWI-negative than DWI-positive group (2 vs 6, p=0.0001), but the median symptom onset-to-MRI time was similar in both groups (108 vs 111 min, p=0.88)., Conclusions: In patients with DWI-negative AIS, symptoms are less severe. Large vessel occlusions, notably in the M2 segment, are more distal at the expense of the M1 segment of MCA. The spaghetti sign remains the most predictive feature of AIS that should be specifically searched in the absence of DWI lesions., Competing Interests: Declaration of competing interest All authors report no competing interests., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Clinical change during inter-hospital transfer for thrombectomy: Incidence, associated factors, and relationship with outcome.
- Author
-
Seners P, Ter Schiphorst A, Wouters A, Yuen N, Mlynash M, Arquizan C, Heit JJ, Kemp S, Christensen S, Sablot D, Wacongne A, Lalu T, Costalat V, Albers GW, and Lansberg MG
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Treatment Outcome, Incidence, Aged, 80 and over, France epidemiology, Thrombectomy methods, Patient Transfer statistics & numerical data, Ischemic Stroke surgery, Ischemic Stroke therapy, Ischemic Stroke epidemiology
- Abstract
Background: Patients with acute ischemic stroke with a large vessel occlusion (LVO) admitted to non endovascular-capable centers often require inter-hospital transfer for thrombectomy. We aimed to describe the incidence of substantial clinical change during transfer, the factors associated with clinical change, and its relationship with 3-month outcome., Methods: We analyzed data from two cohorts of acute stroke patients transferred for thrombectomy to a comprehensive center (Stanford, USA, November 2019 to January 2023; Montpellier, France, January 2015 to January 2017), regardless of whether thrombectomy was eventually attempted. Patients were included if they had evidence of an LVO at the referring hospital and had a National Institute of Health Stroke Scale (NIHSS) score documented before and immediately after transfer. Inter-hospital clinical change was categorized as improvement (⩾4 points and ⩾25% decrease between the NIHSS score in the referring hospital and upon comprehensive center arrival), deterioration (⩾4 points and ⩾25% increase), or stability (neither improvement nor deterioration). The stable group was considered as the reference and was compared to the improvement or deterioration groups separately., Results: A total of 504 patients were included, of whom 22% experienced inter-hospital improvement, 14% deterioration, and 64% were stable. Pre-transfer variables independently associated with clinical improvement were intravenous thrombolysis use, more distal occlusions, and lower serum glucose; variables associated with deterioration included more proximal occlusions and higher serum glucose. On post-transfer imaging, clinical improvement was associated with arterial recanalization and smaller infarct growth and deterioration with larger infarct growth. As compared to stable patients, those with clinical improvement had better 3-month functional outcome (adjusted common odds ratio (cOR) = 2.43; 95% confidence interval (CI) = 1.59-3.71; p < 0.001), while those with deterioration had worse outcome (adjusted cOR = 0.60; 95% CI = 0.37-0.98; p = 0.044)., Conclusion: Substantial inter-hospital clinical changes are frequently observed in LVO-related ischemic strokes, with significant impact on functional outcome. There is a need to develop treatments that improves the clinical status during transfer., Data Access Statement: The data that support the findings of this study are available upon reasonable request., Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr J.J.H. reports consulting fees from Medtronic and MicroVention, and he is a member of the medical and scientific advisory board for iSchemaView; Dr G.W.A. reports stock holdings in iSchemaView; compensation from Biogen, iSchemaView, and Genentech for consultant services. Other authors have nothing to disclose.
- Published
- 2024
- Full Text
- View/download PDF
29. Cerebral Amyloid Angiopathy-Related Inflammation and Biopsy-Positive Primary Angiitis of the CNS: A Comparative Study.
- Author
-
Grangeon L, Boulouis G, Capron J, Bala F, Renard D, Raposo N, Ozkul-Wermester O, Triquenot-Bagan A, Ayrignac X, Wallon D, Gerardin E, Kerschen P, Sablot D, Formaglio M, Pico F, Turc G, Verny M, Humbertjean L, Gaudron M, Vannier S, Dequatre N, Guillon B, Isabel C, Arquizan C, Detante O, Godard S, Casolla B, Levraut M, Gollion C, Gerfaud-Valentin M, Kremer L, Daelman L, Lambert N, Lanthier S, Poppe A, Régent A, Weisenburger-Lile D, Verdure P, Quesney G, Vautier M, Wacongne A, Thouvenot E, Pariente J, Coulette S, Labauge PM, Olivier N, Allou T, Zephir H, Néel A, Bresch S, Terrier B, Martinaud O, Schneckenburger R, Papo T, Comarmond-Ortoli C, Jouvent E, Subréville M, Poncet-Megemont L, Khatib MA, Lun F, Henry C, Magnin E, Thomas Q, Graber M, Boukriche Y, Blanchet-Fourcade G, Ratiu D, Pagnoux C, Touzé E, de Boysson H, Alamowitch S, and Nehme A
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Retrospective Studies, Biopsy, Magnetic Resonance Imaging, Aged, 80 and over, Brain pathology, Brain diagnostic imaging, Adult, Recurrence, Cerebral Amyloid Angiopathy diagnostic imaging, Cerebral Amyloid Angiopathy pathology, Cerebral Amyloid Angiopathy complications, Vasculitis, Central Nervous System diagnostic imaging, Vasculitis, Central Nervous System pathology
- Abstract
Background and Objectives: Cerebral amyloid angiopathy-related inflammation (CAA-RI) and biopsy-positive primary angiitis of the CNS (BP-PACNS) have overlapping clinicoradiologic presentations. It is unknown whether clinical and radiologic features can differentiate CAA-RI from BP-PACNS and whether both diseases have different relapse rates. The objectives of this study were to compare clinicoradiologic presentations and relapse rates in patients with CAA-RI vs BP-PACNS., Methods: Patients with CAA-RI and BP-PACNS were enrolled from 2 retrospective multicenter cohorts. Patients with CAA-RI were biopsy-positive or met probable clinicoradiologic criteria. Patients with BP-PACNS had histopathologic confirmation of CNS angiitis, with no secondary etiology. A neuroradiologist read brain MRIs, blinded to the diagnosis of CAA-RI or BP-PACNS. Clinicoradiologic features were compared using univariable logistic regression models. Relapse rates were compared using a univariable Fine-Gray subdistribution hazard model, with death as a competing risk., Results: This study enrolled 104 patients with CAA-RI (mean age 73 years, 48% female sex) and 52 patients with BP-PACNS (mean age 45 years, 48% female sex). Patients with CAA-RI more often had white matter hyperintense lesions meeting the probable CAA-RI criteria (93% vs 51%, p < 0.001), acute subarachnoid hemorrhage (15% vs 2%, p = 0.02), cortical superficial siderosis (27% vs 4%, p < 0.001), ≥1 lobar microbleed (94% vs 26%, p < 0.001), past intracerebral hemorrhage (17% vs 4%, p = 0.04), ≥21 visible centrum semiovale perivascular spaces (34% vs 4%, p < 0.01), and leptomeningeal enhancement (70% vs 27%, p < 0.001). Patients with BP-PACNS more often had headaches (56% vs 31%, p < 0.01), motor deficits (56% vs 36%, p = 0.02), and nonischemic parenchymal gadolinium enhancement (82% vs 16%, p < 0.001). The prevalence of acute ischemic lesions was 18% in CAA-RI and 22% in BP-PACNS ( p = 0.57). The features with the highest specificity for CAA-RI were acute subarachnoid hemorrhage (98%), cortical superficial siderosis (96%), past intracerebral hemorrhage (96%), and ≥21 visible centrum semiovale perivascular spaces (96%). The probable CAA-RI criteria had a 71% sensitivity (95% CI 44%-90%) and 91% specificity (95% CI 79%-98%) in differentiating biopsy-positive CAA-RI from BP-PACNS. The rate of relapse in the first 2 years after remission was lower in CAA-RI than in BP-PACNS (hazard ratio 0.46, 95% CI 0.22-0.96, p = 0.04)., Conclusion: Clinicoradiologic features differed between patients with CAA-RI and those with BP-PACNS. Specific markers for CAA-RI were hemorrhagic signs of subarachnoid involvement, past intracerebral hemorrhage, ≥21 visible centrum semiovale perivascular spaces, and the probable CAA-RI criteria. A biopsy remains necessary for diagnosis in some cases of CAA-RI. The rate of relapse in the first 2 years after disease remission was lower in CAA-RI than in BP-PACNS.
- Published
- 2024
- Full Text
- View/download PDF
30. Arterial Recanalization During Interhospital Transfer for Thrombectomy.
- Author
-
Seners P, Wouters A, Ter Schiphorst A, Yuen N, Mlynash M, Arquizan C, Heit JJ, Kemp S, Christensen S, Sablot D, Wacongne A, Lalu T, Costalat V, Lansberg MG, and Albers GW
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Aged, 80 and over, Treatment Outcome, Thrombectomy methods, Patient Transfer, Ischemic Stroke surgery, Ischemic Stroke diagnostic imaging, Ischemic Stroke therapy
- Abstract
Background: Patients with acute ischemic stroke harboring a large vessel occlusion admitted to nonendovascular-capable centers often require interhospital transfer for thrombectomy. We evaluated the incidence and predictors of arterial recanalization during transfer, as well as the relationship between interhospital recanalization and clinical outcomes., Methods: We analyzed data from 2 cohorts of patients with an anterior circulation large vessel occlusion transferred for consideration of thrombectomy to a comprehensive center, with arterial imaging at the referring hospital and on comprehensive stroke center arrival. Interhospital recanalization was determined by comparison of the baseline and posttransfer arterial imaging and was defined as revised arterial occlusive lesion (rAOL) score 2b to 3. Pretransfer variables independently associated with interhospital recanalization were studied using multivariable logistic regression analysis., Results: Of the 520 included patients (Montpellier, France, n=237; Stanford, United States, n=283), 111 (21%) experienced interhospital recanalization (partial [rAOL=2b] in 77% and complete [rAOL=3] in 23%). Pretransfer variables independently associated with recanalization were intravenous thrombolysis (adjusted odds ratio, 6.8 [95% CI, 4.0-11.6]), more distal occlusions (intracranial carotid occlusion as reference: adjusted odds ratio, 2.0 [95% CI, 0.9-4.5] for proximal first segment of the middle cerebral artery, 5.1 [95% CI, 2.3-11.5] for distal first segment of the middle cerebral artery, and 5.0 [95% CI, 2.1-11.8] for second segment of the middle cerebral artery), and smaller clot burden (clot burden score 0-4 as reference: adjusted odds ratio, 3.4 [95% CI, 1.5-7.6] for 5-7 and 5.6 [95% CI, 2.4-12.7] for 8-9). Recanalization on arrival at the comprehensive center was associated with less interhospital infarct growth (rAOL, 0-2a: 11.6 mL; rAOL, 2b: 2.2 mL; rAOL, 3: 0.6 mL; P
trend <0.001) and greater interhospital National Institutes of Health Stroke Scale score improvement (0 versus -5 versus -6; Ptrend <0.001). Interhospital recanalization was associated with reduced 3-month disability (adjusted common odds ratio, 2.51 [95% CI, 1.68-3.77]) with greater benefit from complete than partial recanalization., Conclusions: Recanalization is frequently observed during interhospital transfer for thrombectomy and is strongly associated with favorable outcomes, even when partial. Broadening thrombolysis indications in primary centers, and developing therapies that increase recanalization during transfer, will likely improve clinical outcomes., Competing Interests: Disclosures Dr Wouters reports grants from Remmert Adriaan-Laan-Fonds. Dr Arquizan reports compensation from Amgen and Medtronic Vascular, Inc, for other services. Dr Christensen reports stock holdings in iSchemaView. Dr Costalat reports compensation from Penumbra, Inc, MicroVention, Inc, Balt USA, LLC, Stryker Corporation, Medtronic USA, Inc, and Johnson & Johnson Health Care Systems, Inc, for consultant services. Dr Heit reports consulting fees from Medtronic and MicroVention, and he is a member of the Medical and Scientific Advisory Board of iSchemaView. Dr Albers reports stock holdings in iSchemaView and compensation from Biogen, iSchemaView, and Genentech for consultant services. The other authors report no conflicts.- Published
- 2024
- Full Text
- View/download PDF
31. Becoming a thrombectomy-capable stroke center: Clinical and medico-economical effectiveness at the hospital level.
- Author
-
Checkouri T, Sablot D, Varnier Q, Fryder I, Collemiche FL, Azais B, Dargazanli C, Leibinger F, Cagnazzo F, Mahmoudi M, Lefevre PH, Van Damme L, Gascou G, Schmidt J, Arquizan C, Plantard C, Farouil G, and Costalat V
- Abstract
Introduction: Too few patients benefit from endovascular therapy (EVT) in large vessel occlusion acute stroke (LVOS), and various acute stroke care paradigms are currently investigated to reduce these inequalities in health access. We aimed to investigate whether newly set-up thrombectomy-capable stroke centers (TSC) offered a safe, effective and cost-effective procedure., Patients and Methods: This French retrospective study compared the outcomes of LVOS patients with an indication for EVT and treated at the Perpignan hospital before on-site thrombectomy was available (Primary stroke center), and after formation of local radiology team for neurointervention (TSC). Primary endpoints were 3-months functional outcomes, assessed by the modified Rankin scale. Various safety endpoints for ischemic and hemorragic procedural complications were assessed. We conducted a medico-economic analysis to estimate the cost-benefit of becoming a TSC for the hospital., Results: The differences between 422 patients in the PSC and 266 in the TSC were adjusted by the means of weighted logistic regression. Patients treated in the TSC had higher odds of excellent functional outcome (aOR 1.77 [1.16-2.72], p = 0.008), with no significant differences in the rates of procedural complications. The TSC setting shortened onset-to-reperfusion times by 144 min (95% CI [131-155]; p < 0.0001), and was cost-effective after 21 treated LVOS patients. On-site thrombectomy saves 10.825€ per patient for the hospital., Discussion: Our results demonstrate that the TSC setting improves functional outcomes and reduces intra-hospital costs in LVOS patients. TSCs could play a major public health role in acute stroke care and access to EVT., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
32. Endovascular Therapy or Medical Management Alone for Isolated Posterior Cerebral Artery Occlusion: A Multicenter Study.
- Author
-
Sabben C, Charbonneau F, Delvoye F, Strambo D, Heldner MR, Ong E, Ter Schiphorst A, Henon H, Ben Hassen W, Agasse-Lafont T, Legris L, Sibon I, Wolff V, Sablot D, Elhorany M, Preterre C, Nehme N, Soize S, Weisenburger-Lile D, Triquenot-Bagan A, Mione G, Aignatoaie A, Papassin J, Poll R, Béjot Y, Carrera E, Garnier P, Michel P, Saliou G, Mordasini P, Berthezene Y, Costalat V, Bricout N, Albers GW, Mazighi M, Turc G, and Seners P
- Subjects
- Humans, Female, Middle Aged, Aged, Aged, 80 and over, Male, Thrombolytic Therapy, Posterior Cerebral Artery, Thrombectomy, Intracranial Hemorrhages, Treatment Outcome, Ischemic Stroke, Stroke therapy, Endovascular Procedures, Brain Ischemia surgery
- Abstract
Background: Whether endovascular therapy (EVT) added on best medical management (BMM), as compared to BMM alone, is beneficial in acute ischemic stroke with isolated posterior cerebral artery occlusion is unknown., Methods: We conducted a multicenter international observational study of consecutive stroke patients admitted within 6 hours from symptoms onset in 26 stroke centers with isolated occlusion of the first (P1) or second (P2) segment of the posterior cerebral artery and treated either with BMM+EVT or BMM alone. Propensity score with inverse probability of treatment weighting was used to account for baseline between-groups differences. The primary outcome was 3-month good functional outcome (modified Rankin Scale [mRS] score 0-2 or return to baseline modified Rankin Scale). Secondary outcomes were 3-month excellent recovery (modified Rankin Scale score 0-1), symptomatic intracranial hemorrhage, and early neurological deterioration., Results: Overall, 752 patients were included (167 and 585 patients in the BMM+EVT and BMM alone groups, respectively). Median age was 74 (interquartile range, 63-82) years, 329 (44%) patients were female, median National Institutes of Health Stroke Scale was 6 (interquartile range 4-10), and occlusion site was P1 in 188 (25%) and P2 in 564 (75%) patients. Baseline clinical and radiological data were similar between the 2 groups following propensity score weighting. EVT was associated with a trend towards lower odds of good functional outcome (odds ratio, 0.81 [95% CI, 0.66-1.01]; P =0.06) and was not associated with excellent functional outcome (odds ratio, 1.17 [95% CI, 0.95-1.43]; P =0.15). EVT was associated with a higher risk of symptomatic intracranial hemorrhage (odds ratio, 2.51 [95% CI, 1.35-4.67]; P =0.004) and early neurological deterioration (odds ratio, 2.51 [95% CI, 1.64-3.84]; P <0.0001)., Conclusions: In this observational study of patients with proximal posterior cerebral artery occlusion, EVT was not associated with good or excellent functional outcome as compared to BMM alone. However, EVT was associated with higher rates of symptomatic intracranial hemorrhage and early neurological deterioration. EVT should not be routinely recommended in this population, but randomization into a clinical trial is highly warranted.
- Published
- 2023
- Full Text
- View/download PDF
33. Should Patients With Acute Minor Ischemic Stroke With Isolated Internal Carotid Artery Occlusion Be Thrombolysed?
- Author
-
Boulenoir N, Turc G, Ter Schiphorst A, Heldner MR, Strambo D, Laksiri N, Girard Buttaz I, Papassin J, Sibon I, Chausson N, Michel P, Rosso C, Bourdain F, Lamy C, Weisenburger-Lile D, Agius P, Yger M, Obadia M, Sablot D, Legris N, Jung S, Pilgram-Pastor S, Henon H, Bernardaud L, Arquizan C, Baron JC, and Seners P
- Subjects
- Humans, Fibrinolytic Agents therapeutic use, Thrombolytic Therapy methods, Carotid Artery, Internal diagnostic imaging, Retrospective Studies, Treatment Outcome, Anticoagulants therapeutic use, Thrombectomy methods, Ischemic Stroke, Arterial Occlusive Diseases diagnostic imaging, Arterial Occlusive Diseases drug therapy, Arterial Occlusive Diseases complications, Stroke diagnostic imaging, Stroke drug therapy, Stroke etiology, Carotid Artery Diseases complications, Thrombosis drug therapy, Brain Ischemia diagnostic imaging, Brain Ischemia drug therapy, Brain Ischemia complications
- Abstract
Background: We recently reported a worrying 30% rate of early neurological deterioration (END) occurring within 24 hours following intravenous thrombolysis (IVT) in minor stroke with isolated internal carotid artery occlusion (ie, without additional intracranial occlusion), mainly due to artery-to-artery embolism. Here, we hypothesize that in this setting IVT-as compared to no-IVT-may foster END, in particular by favoring artery-to-artery embolism from thrombus fragmentation., Methods: From a large multicenter retrospective database, we compared minor stroke (National Institutes of Health Stroke Scale score <6) isolated internal carotid artery occlusion patients treated within 4.5 hours of symptoms onset with either IVT or antithrombotic therapy between 2006 and 2020 (inclusion date varied among centers). Primary outcome was END within 24 hours (≥4 National Institutes of Health Stroke Scale points increase within 24 hours), and secondary outcomes were END within 7 days (END
7d ) and 3-month modified Rankin Scale score 0 to 1., Results: Overall, 189 patients were included (IVT=95; antithrombotics=94 [antiplatelets, n=58, anticoagulants, n=36]) from 34 centers. END within 24 hours and END7d occurred in 46 (24%) and 60 (32%) patients, respectively. Baseline clinical and radiological variables were similar between the 2 groups, except significantly higher National Institutes of Health Stroke Scale (median 3 versus 2) and shorter onset-to-imaging (124 versus 149min) in the IVT group. END within 24 hours was more frequent following IVT (33% versus 16%, adjusted hazard ratio, 2.01 [95% CI, 1.07-3.92]; P =0.03), driven by higher odds of artery-to-artery embolism (20% versus 9%, P =0.09). However, END7d and 3-month modified Rankin Scale score of 0 to 1 did not significantly differ between the 2 groups (END7d : adjusted hazard ratio, 1.29 [95% CI, 0.75-2.23]; P =0.37; modified Rankin Scale score of 0-1: adjusted odds ratio, 1.1 [95% CI, 0.6-2.2]; P =0.71). END7d occurred earlier in the IVT group: median imaging-to-END 2.6 hours (interquartile range, 1.9-10.1) versus 20.4 hours (interquartile range, 7.8-34.4), respectively, P <0.01., Conclusions: In our population of minor strokes with iICAO, although END rate at 7 days and 3-month outcome were similar between the 2 groups, END-particularly END due to artery-to-artery embolism-occurred earlier following IVT. Prospective studies are warranted to further clarify the benefit/risk profile of IVT in this population.- Published
- 2022
- Full Text
- View/download PDF
34. Predictive value of DWI posterior-circulation lesion volume for 90-day clinical outcome after endovascular treatment of acute basilar artery occlusion: a retrospective single-center study.
- Author
-
Mourand I, Mahmoudi M, Lebars E, Pavillard F, Dargazanli C, Labreuche J, Gaillard N, Ter Schiphorst A, Derraz I, Sablot D, Corti L, Costalat V, Arquizan C, and Cagnazzo F
- Subjects
- Humans, Predictive Value of Tests, Retrospective Studies, Treatment Outcome, Arterial Occlusive Diseases surgery, Basilar Artery diagnostic imaging, Basilar Artery surgery, Endovascular Procedures
- Abstract
Purpose: The relationship between posterior-circulation lesion volume (PCLV) and clinical outcomes is poorly investigated. We aimed to analyze, in patients with acute basilar artery occlusion (ABAO), if pre-endovascular treatment (EVT) PCLV was a predictor of outcomes., Methods: We analyzed consecutive MRI selected, endovascularly treated ABAO patients. Baseline PCLV was measured in milliliters on apparent diffusion-coefficient map reconstruction. Univariable and multivariable logistic models were used to test if PCLV was a predictor of 90-day outcomes. After the received operating characteristic (ROC) analysis, the optimal cut-off was determined to evaluate the prognostic value of PCLV., Results: A total of 110 ABAO patients were included. The median PCLV was 4.4 ml (interquartile range, 1.3-21.2 ml). Successful reperfusion was achieved in 81.8% of cases after EVT. At 90 days, 31.8% of patients had a modified Rankin scale ≤ 2, and the mortality rate was 40.9%. PCLV was an independent predictor of functional independence and mortality (odds ratio [OR]:0.57, 95% confidence interval [CI], 0.34-0.93 and 1.84, 95% CI, 1.23-2.76, respectively). The ROC analysis showed that a baseline PCLV ≤ 8.7 ml was the optimal cut-off to predict the 90-day functional independence (area under the curve [AUC] = 0.68, 95% CI, 0.57-0.79, sensitivity 88.6%, and specificity 49.3%). In addition, a PCLV ≥ 9.1 ml was the optimal cut-off for the prediction of 90-day mortality (AUC = 0.71, 95% CI, 0.61-0.82, sensitivity 80%, and specificity 60%)., Conclusions: Pre-treatment PCLV was an independent predictor of 90-day outcomes in ABAO. A PCLV ≤ 8.7 and ≥ 9.1 ml may identify patients with a higher possibility to achieve independence and a higher risk of death at 90 days, respectively., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
35. Patent foramen ovale closure in stroke patients with migraine in the CLOSE trial. The CLOSE-MIG study.
- Author
-
Mas JL, Guillon B, Charles-Nelson A, Domigo V, Derex L, Massardier E, Arquizan C, Vuillier F, Timsit S, Béjot Y, Detante O, Sablot D, Guidoux C, Sibon I, Dequatre-Ponchelle N, Touzé E, Canaple S, Alamowitch S, Aubry P, Teiger E, Derumeaux G, and Chatellier G
- Subjects
- Adult, Female, Humans, Middle Aged, Platelet Aggregation Inhibitors therapeutic use, Treatment Outcome, Brain Ischemia, Foramen Ovale, Patent complications, Foramen Ovale, Patent surgery, Migraine Disorders complications, Migraine Disorders prevention & control, Septal Occluder Device, Stroke complications, Stroke prevention & control
- Abstract
Background and Purpose: The efficacy of patent foramen ovale (PFO) closure to reduce the frequency of migraine attacks remains controversial., Methods: This was a planned sub-study in migraine patients enrolled in a randomized, clinical trial designed to assess the superiority of PFO closure plus antiplatelet therapy over antiplatelet therapy alone to prevent stroke recurrence in patients younger than 60 years with a PFO-associated cryptogenic ischaemic stroke. The main outcome was the mean annual number of migraine attacks in migraine patients with aura and in those without aura, as recorded at each follow-up visit by study neurologists., Results: Of 473 patients randomized to PFO closure or antiplatelet therapy, 145 (mean age 41.9 years; women 58.6%) had migraine (75 with aura and 70 without aura). Sixty-seven patients were randomized to PFO closure and 78 to antiplatelet therapy. During a mean follow-up of about 5 years, there were no differences between antiplatelet-only and PFO closure groups in the mean annual number of migraine attacks, both in migraine patients with aura (9.2 [11.9] vs. 12.0 [19.1], p = 0.81) and in those without aura (12.1 [16.1] vs. 11.8 [18.4], p > 0.999). There were no differences between treatment groups regarding cessation of migraine attacks, migraine-related disability at 2 years and use of migraine-preventive drugs during follow-up., Conclusions: In young and middle-aged adults with PFO-associated cryptogenic stroke and migraine, PFO closure plus antiplatelet therapy did not reduce the mean annual number of migraine attacks compared to antiplatelet therapy alone, in migraine patients both with and without aura., (© 2021 European Academy of Neurology.)
- Published
- 2021
- Full Text
- View/download PDF
36. Usefulness of a single-parameter tool for the prediction of large vessel occlusion in acute stroke.
- Author
-
Leibinger F, Allou T, Van Damme L, Jebali C, Arquizan C, Farouil G, Laverdure A, Gaillard N, Ibanez M, Smadja P, Dutray A, Tardieu M, Nguyen Them L, Ousji A, Jurici S, Gascou G, Bensalah ZM, Olivier N, Damon F, Chaabane W, Fadat B, Lachcar M, Mas J, Mourand I, Ferraro A, Heve D, Dumitrana A, Blenet JC, Aptel S, Costalat V, Bonafe A, Ortega L, and Sablot D
- Subjects
- Aged, Emergency Service, Hospital, Female, Humans, Male, Triage, Brain Ischemia, Emergency Medical Services, Stroke complications, Stroke therapy
- Abstract
Background: In acute stroke, large vessel occlusion (LVO) should be promptly identified to guide patient's transportation directly to comprehensive stroke centers (CSC) for mechanical thrombectomy (MT). In many cases, prehospital multi-parameter scores are used by trained emergency teams to identify patients with high probability of LVO. However, in several countries, the first aid organization without intervention of skilled staff precludes the on-site use of such scores. Here, we assessed the accuracy of LVO prediction using a single parameter (i.e. complete hemiplegia) obtained by bystander's telephone-based witnessing., Patients and Methods: This observational, single-center study included consecutive patients who underwent intravenous thrombolysis at the primary stroke center and/or were directly transferred to a CSC for MT, from January 1, 2015 to March 1, 2020. We defined two groups: patients with initial hemiplegia (no movement in one arm and leg and facial palsy) and patients without initial hemiplegia, on the basis of a bystander's witnessing., Results: During the study time, 874 patients were included [mean age 73 years (SD 13.8), 56.7% men], 320 with initial hemiplegia and 554 without. The specificity of the hemiplegia criterion to predict LVO was 0.88, but its sensitivity was only 0.53., Conclusion: Our results suggest that the presence of hemiplegia as witnessed by a bystander can predict LVO with high specificity. This single criterion could be used for decision-making about direct transfer to CSC for MT when the absence of emergency skilled staff precludes the patient's on-site assessment, especially in regions distant from a CSC.
- Published
- 2021
- Full Text
- View/download PDF
37. Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis Alone.
- Author
-
Seners P, Ben Hassen W, Lapergue B, Arquizan C, Heldner MR, Henon H, Perrin C, Strambo D, Cottier JP, Sablot D, Girard Buttaz I, Tamazyan R, Preterre C, Agius P, Laksiri N, Mechtouff L, Béjot Y, Duong DL, Mounier-Vehier F, Mione G, Rosso C, Lucas L, Papassin J, Aignatoaie A, Triquenot A, Carrera E, Niclot P, Obadia A, Lyoubi A, Garnier P, Crainic N, Wolff V, Tracol C, Philippeau F, Lamy C, Soize S, Baron JC, and Turc G
- Subjects
- Administration, Intravenous methods, Aged, Aged, 80 and over, Cerebrovascular Disorders diagnostic imaging, Cerebrovascular Disorders epidemiology, Cohort Studies, Female, Fibrinolytic Agents administration & dosage, Humans, Male, Mechanical Thrombolysis methods, Middle Aged, Nervous System Diseases diagnostic imaging, Nervous System Diseases epidemiology, Nervous System Diseases therapy, Predictive Value of Tests, Retrospective Studies, Stroke diagnostic imaging, Stroke epidemiology, Thrombolytic Therapy methods, Administration, Intravenous trends, Cerebrovascular Disorders therapy, Mechanical Thrombolysis trends, Stroke therapy, Thrombolytic Therapy trends, Tissue Plasminogen Activator administration & dosage
- Abstract
Importance: The best reperfusion strategy in patients with acute minor stroke and large vessel occlusion (LVO) is unknown. Accurately predicting early neurological deterioration of presumed ischemic origin (ENDi) following intravenous thrombolysis (IVT) in this population may help to select candidates for immediate transfer for additional thrombectomy., Objective: To develop and validate an easily applicable predictive score of ENDi following IVT in patients with minor stroke and LVO., Design, Setting, and Participants: This multicentric retrospective cohort included 729 consecutive patients with minor stroke (National Institutes of Health Stroke Scale [NIHSS] score of 5 or less) and LVO (basilar artery, internal carotid artery, first [M1] or second [M2] segment of middle cerebral artery) intended for IVT alone in 45 French stroke centers, ie, including those who eventually received rescue thrombectomy because of ENDi. For external validation, another cohort of 347 patients with similar inclusion criteria was collected from 9 additional centers. Data were collected from January 2018 to September 2019., Main Outcomes and Measures: ENDi, defined as 4 or more points' deterioration on NIHSS score within the first 24 hours without parenchymal hemorrhage on follow-up imaging or another identified cause., Results: Of the 729 patients in the derivation cohort, 335 (46.0%) were male, and the mean (SD) age was 70 (15) years; of the 347 patients in the validation cohort, 190 (54.8%) were male, and the mean (SD) age was 69 (15) years. In the derivation cohort, the median (interquartile range) NIHSS score was 3 (1-4), and the occlusion site was the internal carotid artery in 97 patients (13.3%), M1 in 207 (28.4%), M2 in 395 (54.2%), and basilar artery in 30 (4.1%). ENDi occurred in 88 patients (12.1%; 95% CI, 9.7-14.4) and was strongly associated with poorer 3-month outcomes, even in patients who underwent rescue thrombectomy. In multivariable analysis, a more proximal occlusion site and a longer thrombus were independently associated with ENDi. A 4-point score derived from these variables-1 point for thrombus length and 3 points for occlusion site-showed good discriminative power for ENDi (C statistic = 0.76; 95% CI, 0.70-0.82) and was successfully validated in the validation cohort (ENDi rate, 11.0% [38 of 347]; C statistic = 0.78; 95% CI, 0.70-0.86). In both cohorts, ENDi probability was approximately 3%, 7%, 20%, and 35% for scores of 0, 1, 2 and 3 to 4, respectively., Conclusions and Relevance: The substantial ENDi rates observed in these cohorts highlights the current debate regarding whether to directly transfer patients with IVT-treated minor stroke and LVO for additional thrombectomy. Based on the strong associations observed, an easily applicable score for ENDi risk prediction that may assist decision-making was derived and externally validated.
- Published
- 2021
- Full Text
- View/download PDF
38. Symptomatic isolated internal carotid artery occlusion with initial medical management: a monocentric cohort.
- Author
-
Ter Schiphorst A, Gaillard N, Dargazanli C, Mourand I, Corti L, Charif M, Ayrignac X, Lippi A, Bouly S, Thibault L, Sablot D, Blanchet-Fourcade G, Landragin N, Costalat V, Duflos C, and Arquizan C
- Subjects
- Carotid Artery, Internal diagnostic imaging, Humans, Retrospective Studies, Thrombectomy, Treatment Outcome, Brain Ischemia, Endovascular Procedures, Stroke diagnostic imaging, Stroke drug therapy
- Abstract
Background: Symptomatic isolated carotid artery occlusions (ICAO) can lead to disability, recurrent stroke, and mortality, but natural history and best therapeutic management remain poorly known. The objective of this study was to describe our cohort of ICAO patients with an initial medical management., Methods: We conducted a retrospective study including consecutive patients admitted to our Comprehensive Stroke Center for ICAO within 24 h after stroke onset between January 2016 and September 2018. Patients with immediate endovascular therapy (EVT) were excluded. Medical treatment was based on anticoagulation (delayed by 24 h if intravenous thrombolysis was performed). 'Rescue' EVT was considered if first-week neurological deterioration (FWND) occurred., Results: Fifty-six patients were included, with a median National Institutes of Health Stroke Scale (NIHSS) of 3. Eleven patients (20%) had FWND during the first week, four benefited from rescue EVT. A mismatch volume > 40 cc on initial perfusion imaging and FLAIR vascular hyperintensities were associated with FWND (p = 0.007 and p = 0.009, respectively). Thirty-eight patients (69%) had a good outcome (modified Rankin Scale mRS 0-2) at 3 months, 36 (69%) had an excellent outcome (mRS 0-1). Seventeen patients (38%) had carotid patency on 3-month control imaging. Recurrences occurred in six (13%) of the survivors (mean follow-up: 13.6 months)., Conclusion: Our results suggest that the prognosis of patients with acute ICAO was favorable with a medical strategy, albeit a substantial rate of FWND and recurrence. FWND was well predicted by a core-perfusion mismatch volume > 40 cc. Randomized controlled trials are necessary to assess the benefit of EVT in ICAO.
- Published
- 2021
- Full Text
- View/download PDF
39. Intended Bridging Therapy or Intravenous Thrombolysis Alone in Minor Stroke With Basilar Artery Occlusion.
- Author
-
Seners P, Dargazanli C, Piotin M, Sablot D, Bracard S, Niclot P, Baron JC, and Turc G
- Subjects
- Aged, Aged, 80 and over, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Propensity Score, Retrospective Studies, Risk Factors, Stroke complications, Stroke diagnostic imaging, Treatment Outcome, Vertebrobasilar Insufficiency complications, Vertebrobasilar Insufficiency diagnostic imaging, Stroke therapy, Thrombectomy methods, Thrombolytic Therapy methods, Vertebrobasilar Insufficiency therapy
- Abstract
Background and Purpose: Whether bridging therapy (intravenous thrombolysis [IVT] followed by mechanical thrombectomy) is superior to IVT alone in minor stroke with basilar artery occlusion remains uncertain., Methods: Multicentric retrospective observational study of consecutive minor stroke patients (National Institutes of Health Stroke Scale score ≤5) with basilar artery occlusion intended for IVT alone or bridging therapy. Propensity-score weighting was used to reduce baseline between-groups differences, and residual imbalance was addressed through adjusted logistic regression, with excellent outcome (3-month modified Rankin Scale score 0-1) as the dependent variable., Results: Fifty-seven patients were included (28 and 29 in the bridging therapy and IVT alone groups, respectively). Following propensity-score weighting, the distribution of baseline clinical and radiological variables was similar across the 2 patient groups, except age, posterior circulation Alberta Stroke Program Early CT Score, history of hypertension and smoking, and onset-to-IVT time. Compared with IVT alone, bridging therapy was associated with excellent outcome (adjusted odds ratio=3.37 [95% CI, 1.13-10.03]; P =0.03). No patient experienced symptomatic intracranial hemorrhage., Conclusions: Our results suggest that bridging therapy may be superior to IVT alone in minor stroke with basilar artery occlusion.
- Published
- 2021
- Full Text
- View/download PDF
40. Complications During Inter-Hospital Transfer of Patients with Acute Ischemic Stroke for Endovascular Therapy.
- Author
-
Sablot D, Leibinger F, Dumitrana A, Duchateau N, Van Damme L, Farouil G, Gaillard N, Lachcar M, Benayoun L, Arquizan C, Ibanez M, Coll F, Fadat B, Nguyen Them L, Desmond L, Allou T, Smadja P, Ferraro-Allou A, Mourand I, Dutray A, Pujol C, Tardieu M, Jurici S, Bonnec JM, Olivier N, Mas J, Costalat V, and Bonafe A
- Subjects
- Brain Ischemia therapy, Hospitals, Humans, Ischemic Stroke therapy, Brain Ischemia complications, Emergency Medical Services, Endovascular Procedures, Ischemic Stroke complications, Patient Transfer
- Abstract
Purpose : Few data are available on complications occurring during inter-hospital transfer from a primary stroke center (PSC) to a comprehensive stroke center (CSC) for endovascular treatment (EVT) after large vessel occlusion (LVO). Therefore, we prospectively studied data from consecutive patients transferred from our PSC to the next CSC during 4 years to determine the incidence and risk factors of complications during transfer. Methods : This observational, single-center study included consecutive patients transferred from January 1, 2015 to December 31, 2018. During inter-hospital transfer, all medical incidents were systematically recorded. A new complete clinical examination was performed on arrival at the CSC. Results : Among the 253 patients transferred to the CSC during the study period, 68 (26.9%) had one or more complications. In 11 patients (4.3%) these were life-threatening and required emergency intervention by a physician. Baseline characteristics were not different between patients with and without complications, except for the LVO location. Specifically, basilar artery (BA) occlusion was strongly associated with complications during the transport (p < 0.0005). Conclusion: Complications occurred in 26.9% of patients during transfer. Only BA occlusion could predict complication during transfer. Future studies should identify variables to help stratifying patients at high and low risk of complications during transportation.
- Published
- 2020
- Full Text
- View/download PDF
41. Predictors of Favorable Outcome after Endovascular Thrombectomy in MRI: Selected Patients with Acute Basilar Artery Occlusion.
- Author
-
Mahmoudi M, Dargazanli C, Cagnazzo F, Derraz I, Arquizan C, Wacogne A, Labreuche J, Bonafe A, Sablot D, Lefevre PH, Gascou G, Gaillard N, Scott C, Costalat V, and Mourand I
- Subjects
- Aged, Arterial Occlusive Diseases complications, Arterial Occlusive Diseases surgery, Basilar Artery pathology, Cerebral Angiography methods, Female, Humans, Magnetic Resonance Imaging methods, Male, Middle Aged, Reperfusion, Retrospective Studies, Thrombotic Stroke etiology, Basilar Artery surgery, Endovascular Procedures methods, Thrombectomy methods, Thrombotic Stroke surgery, Treatment Outcome
- Abstract
Background and Purpose: Clinical outcomes after endovascular treatment for acute basilar artery occlusions need further investigation. Our aim was to analyze predictors of a 90-day good functional outcome defined as mRS 0-2 after endovascular treatment in MR imaging-selected patients with acute basilar artery occlusions., Materials and Methods: We analyzed consecutive MR imaging-selected patients with acute basilar artery occlusions endovascularly treated within the first 24 hours after symptom onset. Successful and complete reperfusion was defined as modified TICI scores 2b-3 and 3, respectively. Outcome at 90 days was analyzed in univariate and multivariate analysis regarding baseline patient treatment characteristics and periprocedural outcomes., Results: One hundred ten patients were included. In 10 patients, endovascular treatment was aborted for failed proximal/distal access. Overall, successful reperfusion was achieved in 81.8% of cases ( n = 90; 95% CI, 73.3%-88.6%). At 90 days, favorable outcome was 31.8%, with a mortality rate of 40.9%; the prevalence of symptomatic intracranial hemorrhage within 24 hours was 2.7%. The median time from symptom onset to groin puncture was 410 minutes (interquartile range, 280-540 minutes). In multivariable analysis, complete reperfusion (OR = 6.59; 95% CI, 2.17-20.03), lower pretreatment NIHSS (OR = 0.77; 95% CI, 0.64-0.94), the presence of posterior communicating artery collateral flow (OR = 2.87; 95% CI, 1.05-7.84), the absence of atrial fibrillation (OR = 0.18; 95% CI, 0.03-0.99), and intravenous thrombolysis administration (OR = 2.75; 95% CI, 1.04-7.04) were associated with 90-day favorable outcome., Conclusions: In our series of MR imaging-selected patients with acute basilar artery occlusions, complete reperfusion was the strongest predictor of a good outcome. Lower pretreatment NIHSS, the presence of posterior communicating artery collateral flow, the absence of atrial fibrillation, and intravenous thrombolysis administration were associated with favorable outcome., (© 2020 by American Journal of Neuroradiology.)
- Published
- 2020
- Full Text
- View/download PDF
42. Bridging Therapy or IV Thrombolysis in Minor Stroke with Large Vessel Occlusion.
- Author
-
Seners P, Perrin C, Lapergue B, Henon H, Debiais S, Sablot D, Girard Buttaz I, Tamazyan R, Preterre C, Laksiri N, Mione G, Arquizan C, Lucas L, Baron JC, and Turc G
- Subjects
- Aged, Aged, 80 and over, Brain Ischemia drug therapy, Brain Ischemia surgery, Combined Modality Therapy, Endovascular Procedures, Female, Humans, Male, Middle Aged, Retrospective Studies, Stroke drug therapy, Stroke surgery, Thrombectomy methods, Treatment Outcome, Brain Ischemia therapy, Fibrinolytic Agents therapeutic use, Stroke therapy, Thrombolytic Therapy methods
- Abstract
Objective: Whether bridging therapy (intravenous thrombolysis [IVT] followed by endovascular treatment) is superior to IVT alone in minor stroke with large vessel occlusion (LVO) is unknown., Methods: Multicentric retrospective observational study including, in intention-to-treat, consecutive IVT-treated minor strokes (National Institutes of Health Stroke Scale [NIHSS] ≤ 5) with LVO, with or without additional mechanical thrombectomy. Propensity-score (inverse probability of treatment weighting) was used to reduce baseline between-groups differences. The primary outcome was excellent outcome, that is, modified Rankin score 0 to 1 at 3 months follow-up., Results: Overall, 598 patients were included (214 and 384 in the bridging therapy and IVT groups, respectively). Following propensity-score weighting, the distribution of baseline clinical and radiological variables was similar across the two patient groups. Compared with IVT alone, bridging therapy was not associated with excellent outcome (odds ratio [OR] = 0.96; 95% confidence interval [CI] = 0.75-1.24; p = 0.76), but was associated with symptomatic intracranial hemorrhage (OR = 3.01; 95% CI = 1.77-5.11; p < 0.0001). Occlusion site was a strong modifier of the effect of bridging therapy on outcome (p
interaction < 0.0001), with bridging therapy associated with higher odds of excellent outcome in proximal M1 (OR = 3.26; 95% CI = 1.67-6.35; p = 0.0006) and distal M1 (OR = 1.69; 95% CI = 1.01-2.82; p = 0.04) occlusions, but with lower odds of excellent outcome for M2 (OR = 0.53; 95% CI = 0.38-0.75; p = 0.0003) occlusions. Bridging therapy was associated with higher rates of symptomatic intracranial hemorrhage in M2 occlusions only (OR = 4.40; 95% CI = 2.20-8.83; p < 0.0001)., Interpretation: Although overall outcomes were similar in intended bridging therapy as compared to intended IVT alone in minor strokes with LVO, our results suggest that intended bridging therapy may be beneficial in M1 occlusions, whereas the benefit-risk profile may favor IVT alone in M2 occlusions. ANN NEUROL 2020 ANN NEUROL 2020;88:160-169., (© 2020 American Neurological Association.)- Published
- 2020
- Full Text
- View/download PDF
43. Mechanical Recanalization after Transfer from a Distant Primary Stroke Center: Effectiveness and Future Directions.
- Author
-
Farouil G, Sablot D, Leibinger F, Van Damme L, Coll F, Gaillard N, Ibanez M, Smadja P, Benayoun L, Dutray A, Tardieu M, Nguyen Them L, Bonnec JM, Jurici S, Bensalah ZM, Olivier N, Desmond L, Fadat B, Bertrand JL, Mas J, Akouz A, Allou T, Mourand I, Ferraro-Allou A, Dumitrana A, Aptel S, Arquizan C, Costalat V, and Bonafe A
- Subjects
- Aged, Aged, 80 and over, Disability Evaluation, Female, Humans, Male, Middle Aged, Prospective Studies, Recovery of Function, Registries, Risk Factors, Stroke diagnosis, Stroke physiopathology, Time Factors, Treatment Outcome, Comprehensive Health Care, Endovascular Procedures adverse effects, Health Services Accessibility, Regional Health Planning, Stroke therapy, Time-to-Treatment, Transportation of Patients
- Abstract
Introduction: Little is known about the effectiveness of endovascular treatment (EVT) in patients with acute ischemic stroke (AIS) due to large vessel occlusion (LVO) admitted to a primary stroke center (PSC). The aim of this study was to assess EVT effectiveness after transfer from a PSC to a distant (156 km apart; 1.5 hour by car) comprehensive stroke center (CSC), and to discuss perspectives to improve access to EVT, if indicated., Patients and Method: Analysis of the data collected in a 6-year prospective registry of patients admitted to a PSC for AIS due to LVO and selected for transfer to a distant CSC for EVT. The rate of transfer, futile transfer, EVT, reperfusion (thrombolysis in cerebral infarction score ≥2b-3), and relevant time measures were determined., Results: Among the 529 patients eligible, 278 (52.6%) were transferred and 153 received EVT (55% of transferred patients) followed by reperfusion in 115 (overall reperfusion rate: 21.7%). Median times (interquartile range) were: 90 minutes (76-110) for PSC-door-in to PSC-door-out, 88 minutes (65-104) for PSC-door-out to CSC-door-in, 262 minutes (239-316) for PSC-imaging to reperfusion, and 393 minutes (332-454) for symptom onset to reperfusion. At 3 months, rates of favorable outcome (modified Rankin Scale 0-2) were not significantly different between patients eligible for EVT (42.4%), transferred patients (49.1%) and patients who underwent EVT (34.1%)., Discussion and Conclusions: Our study suggests that transfer to a distant CSC is associated with reduced access to early EVT. These results argue in favor of on-site EVT at high volume PSCs that are distant from the CSC., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
44. Shortening time to reperfusion after transfer from a primary to a comprehensive stroke center.
- Author
-
Sablot D, Farouil G, Laverdure A, Arquizan C, and Bonafe A
- Abstract
Background: This study assessed whether a quality improvement (QI) process to streamline transfer from a primary stroke center (PSC) to a comprehensive stroke center (CSC) could reduce the delay of reperfusion by mechanical thrombectomy (MT)., Methods: From 2015 to 2017, a QI process was implemented with specific interventions to reduce door-in-to-door-out (DIDO) time in a high volume PSC, and speed up interhospital transfer and inhospital processes at the CSC. Clinical characteristics and time metrics were compared in the QI (2015-2017; n = 157) and pre-QI cohorts (2012-2014; n = 121)., Results: During the QI process, the median symptom onset to reperfusion time was reduced by 50 minutes (367 vs 417 minutes in the pre-QI cohort, p < 0.04), with a substantial 40-minute DIDO reduction (78 vs 118 minutes, p < 0.01), related to the faster administration of IV thrombolysis (median door-to-needle time: 49 vs 82 minutes, p = 0.0001). The door-to-door time was shortened (170 vs 205 minutes, p = 0.002), but not the transfer time (92 vs 87 minutes, p = 0.5). The QI process had no effect on the prehospital phase (77 vs 76 minutes, p = 0.83) and on the time from MRI imaging at the PSC to reperfusion (252 vs 288 minutes, p = 0.12). The rate of modified Rankin Scale score 0-2 at 90 days was comparable in the pre-QI and QI cohorts., Conclusions: A QI process can reduce the reperfusion therapy delay in a distant CSC; however, we could not demonstrate that it can also improve the outcome of patients who undergo MT., (© 2019 American Academy of Neurology.)
- Published
- 2019
- Full Text
- View/download PDF
45. Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.
- Author
-
Ayrignac X, Rigau V, Lhermitte B, Vincent T, de Champfleur NM, Carra-Dalliere C, Charif M, Collongues N, de Seze J, Hebbadj S, Ahle G, Oesterlé H, Cotton F, Durand-Dubief F, Marignier R, Vukusic S, Taithe F, Cohen M, Guennoc AM, Kerbrat A, Edan G, Carsin-Nicol B, Allou T, Sablot D, Thouvenot E, Ruet A, Magy L, Boncoeur-Martel MP, Labauge P, and Kremer S
- Subjects
- Acute Disease, Adult, Aged, Cohort Studies, Female, Humans, Male, Middle Aged, Multiple Sclerosis diagnostic imaging, Multiple Sclerosis epidemiology, Neuromyelitis Optica diagnostic imaging, Neuromyelitis Optica epidemiology, Retrospective Studies, Young Adult, Aquaporin 4, Demyelinating Diseases diagnostic imaging, Demyelinating Diseases epidemiology, Magnetic Resonance Imaging methods
- Abstract
Background: The diagnosis of atypical inflammatory demyelinating lesions can be difficult. Brain biopsy is often required to exclude neoplasms. Moreover, the relationship between these lesions and multiple sclerosis and NMOSD is not clear., Objectives: Our objectives were to describe radiological and pathological characteristics of patients with acute inflammatory demyelinating lesions., Methods: We retrospectively identified patients with brain biopsy performed for diagnostic uncertainty revealing a demyelinating lesion. A complete clinical, biological, radiological and pathological analysis was performed., Results: Twenty patients (15 with a single lesion) were included. MRI disclosed a wide range of lesions including infiltrative lesions (40%), ring-like lesion (15%) Baló-like lesion (15%) and acute haemorrhagic leukoencephalitis (20%). In spite of a marked heterogeneity, some findings were common: a peripheral B1000 hyperintense rim (70%), a slight oedema with mild mass effect (75%) and an open-rim peripheral enhancement (75%). Histopathology revealed that all cases featured macrophages distributed throughout, extensive demyelination, axonal preservation and absence of haemorrhagic changes. In the majority of cases, macrophages were the predominant inflammatory infiltrate and astrocytes were reactive and dystrophic. Aquaporin-4 staining was systematically preserved. After a mean follow-up of 5 years (1-12), 16/20 patients had a diagnosis of monophasic acute atypical inflammatory demyelinating lesion. One patient was diagnosed with MS and 3 with AQP4 negative NMOSD., Discussion: Although imaging findings in patients with atypical inflammatory demyelinating lesions are heterogeneous, some common features such as peripheral DWI hyperintense rim with open-rim enhancement and absence of oedema argue in favour of a demyelinating lesion and should preclude a brain biopsy. In this context, AQP4 staining is systematically preserved and argues against an AQP4-positive NMOSD. Moreover, long-term follow-up is characterized by low recurrence rate.
- Published
- 2019
- Full Text
- View/download PDF
46. Futile inter-hospital transfer for mechanical thrombectomy in a semi-rural context: analysis of a 6-year prospective registry.
- Author
-
Sablot D, Dumitrana A, Leibinger F, Khlifa K, Fadat B, Farouil G, Allou T, Coll F, Mas J, Smadja P, Ferraro-Allou A, Mourand I, Dutray A, Tardieu M, Jurici S, Bonnec JM, Olivier N, Cardini S, Damon F, Van Damme L, Aptel S, Gaillard N, Marquez AM, Nguyen Them L, Ibanez M, Arquizan C, Costalat V, and Bonafe A
- Subjects
- Aged, Aged, 80 and over, Cerebral Infarction diagnostic imaging, Cerebral Infarction epidemiology, Cerebral Infarction therapy, Female, Hospitals trends, Humans, Magnetic Resonance Imaging methods, Male, Middle Aged, Prospective Studies, Retrospective Studies, Stroke diagnostic imaging, Stroke epidemiology, Time Factors, Treatment Outcome, Hospitalization trends, Mechanical Thrombolysis methods, Patient Transfer methods, Registries, Rural Population, Stroke therapy
- Abstract
Background and Purpose: Inter-hospital transfer for mechanical thrombectomy (MT) might result in the transfer of patients who finally will not undergo MT (ie, futile transfers [FT]). This study evaluated FT frequency in a primary stroke center (PSC) in a semi-rural area and at 156 km from the comprehensive stroke center (CSC)., Methodology: Retrospective analysis of data collected in a 6-year prospective registry concerning patients admitted to our PSC within 4.5 hours of acute ischemic stroke (AIS) symptom onset, with MR angiography indicating the presence of large vessel occlusion (LVO) without large cerebral infarction (DWI-ASPECT ≥5), and selected for transfer to the CSC to undergo MT. Futile transfer rate and reasons were determined, and the relevant time measures recorded., Results: Among the 529 patients screened for MT, 278 (52.6%) were transferred to the CSC. Futile transfer rate was 45% (n=125/278) and the three main reasons for FT were: clinical improvement and reperfusion on MRI on arrival at the CSC (58.4% of FT); clinical worsening and/or infarct growth (16.8%); and longer than expected inter-hospital transfer time (11.2%). Predictive factors of FT due to clinical improvement/reperfusion on MRI could not be identified. Baseline higher NIHSS (21 vs 17; P=0.01) and lower DWI-ASPECT score (5 vs 7; P=0.001) were associated with FT due to clinical worsening/infarct growth on MRI., Conclusions: In our setting, 45% of transfers for MT were futile. None of the baseline factors could predict FT, but the initial symptom severity was associated with FT caused byclinical worsening/infarct growth., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
47. A Regional Network Organization for Thrombectomy for Acute Ischemic Stroke in the Anterior Circulation; Timing, Safety, and Effectiveness.
- Author
-
Mourand I, Malissart P, Dargazanli C, Nogue E, Bouly S, Gaillard N, Boukriche Y, Corti L, Picot MC, Beaufils O, Chbicheb M, Sablot D, Bonafe A, Costalat V, and Arquizan C
- Subjects
- Aged, Brain Infarction diagnosis, Brain Infarction mortality, Brain Infarction physiopathology, Disability Evaluation, Feasibility Studies, Female, Fibrinolytic Agents adverse effects, Humans, Infusions, Intravenous, Male, Middle Aged, Recovery of Function, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Brain Infarction surgery, Delivery of Health Care, Integrated organization & administration, Fibrinolytic Agents administration & dosage, Mechanical Thrombolysis adverse effects, Mechanical Thrombolysis mortality, Patient Transfer organization & administration, Regional Health Planning organization & administration, Thrombectomy adverse effects, Thrombectomy mortality, Time-to-Treatment organization & administration
- Abstract
Background: Mechanical thrombectomy (MT) in association with intravenous thrombolysis is recommended for treatment of acute ischemic stroke (AIS), with large vessel occlusion (LVO) in the anterior circulation. Because MT is only available in comprehensive stroke centers (CSC), the challenge of stroke organization is to ensure equitable access to the fastest endovascular suite. Our aim was to evaluate the feasibility, efficacy, and safety of MT in patients initially managed in 1 CSC (mothership), compared with patients first managed in primary stroke center (PSC), and then transferred to the CSC for MT (drip-and-ship)., Methods: We retrospectively analyzed 179 consecutive patients (93 in the mothership group and 86 in the drip-and-ship group), with AIS secondary to LVO in the anterior cerebral circulation and a clinical-radiological mismatch (NIHSS ≥ 8 and DWI-ASPECT score ≥5), up to 6 hours after symptoms onset. We evaluated 3-month functional modified Rankin scale (mRS), periprocedural time management, mortality, and symptomatic intracranial haemorrhage (sICH)., Results: Despite significant longer process time in the drip-and-ship group, mRS ≤ 2 at 3 months (39.8% versus 44.1%, P = .562), Thrombolysis in cerebral infarction 2b-3 (85% versus 78%, P = .256), and sICH (7.0% versus 9.7%, P = .515) were similar in both group regardless of baseline clinical or radiological characteristics. After multivariate logistic regression, the predictive factors for favorable outcome were age (odds ratio [OR]
-5years = 1.32, P < .001), initial NIHSS (OR-5points = 1.59, P = .010), absence of diabetes (OR = 3.35, P = .075), and the delay magnetic resonance imagining-puncture (OR-30min = 1.16, P = .048)., Conclusions: Our study showed encouraging results from a regional protocol of MT comparing patients transferred from PSC or brought directly in CSC., (Copyright © 2018. Published by Elsevier Inc.)- Published
- 2019
- Full Text
- View/download PDF
48. Which Patients Require Physician-Led Inter-Hospital Transport in View of Endovascular Therapy?
- Author
-
Leibinger F, Sablot D, Van Damme L, Gaillard N, Nguyen Them L, Lachcar M, Duchateau N, Arquizan C, Farouil G, Ibanez M, Pujol C, Fadat B, Allou T, Coll F, Benayoun L, Mas J, Smadja P, Ferraro-Allou A, Mourand I, Dutray A, Tardieu M, Jurici S, Bonnec JM, Olivier N, Cardini S, Aptel S, Marquez AM, Dumitrana A, Costalat V, and Bonafe A
- Subjects
- Aged, Aged, 80 and over, Brain Ischemia diagnosis, Clinical Decision-Making, Female, France, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Assessment, Risk Factors, Stroke diagnosis, Time Factors, Brain Ischemia therapy, Emergency Medical Technicians, Endovascular Procedures adverse effects, Health Services Accessibility, Patient Transfer, Physician's Role, Stroke therapy, Time-to-Treatment
- Abstract
Introduction: The current guidelines advocate the implementation of stroke networks to organize endovascular treatment (ET) for patients with acute ischemic stroke due to large vessel occlusion (LVO) after transfer from a Primary Stroke Centre (PSC) to a Comprehensive Stroke Centre (CSC). In France and in many other countries around the world, these transfers are carried out by a physician-led mobile medical team. However, with the recent broadening of ET indications, their availability is becoming more and more critical. Here, we retrospectively analysed data of patients transferred from a PSC to a CSC for potential ET to identify predictive factors of major complications (MC) at departure and during transport that absolutely require the presence of a physician during interhospital transfer., Methods: This observational, single-centre study included patients with evidence of intracranial LVO transferred for ET from Perpignan to a 156 km-distant CSC between January 1, 2015 and -December 31, 2018. We compared 2 groups: MC group (patients who required emergency intervention by the medical team due to life-threatening complications, including need of mechanical ventilation at departure) and non-MC group (all other patients who experienced no or only minor complications that could be managed by the emergency paramedics alone)., Results: Among the 253 patients who were transferred to the CSC, 185 (73.1%) had no complication, 57 (22.6%) minor complications, and 11 (4.3%) had MC. In multivariate analysis, MC was associated with basilar artery (BA) occlusion (p < 0.0001), initial National Institute of Health Stroke Scale (NIHSS) score >22 (p < 0.005), and history of atrial fibrillation (p < 0.04). Among the 168 patients treated with intravenous thrombolysis (IVT), only 1 patient (0.6%) had MC due to an IVT-related adverse event during transfer., Conclusions: Physician-led inter-hospital transports are warranted for patients with BA occlusion, initial NIHSS score >22, or history of atrial fibrillation. For the other patients, transfer without a physician may be considered, even if treated with IVT., (© 2019 S. Karger AG, Basel.)
- Published
- 2019
- Full Text
- View/download PDF
49. Controlled Education of patients after Stroke (CEOPS)- nurse-led multimodal and long-term interventional program involving a patient's caregiver to optimize secondary prevention of stroke: study protocol for a randomized controlled trial.
- Author
-
Mendyk AM, Duhamel A, Bejot Y, Leys D, Derex L, Dereeper O, Detante O, Garcia PY, Godefroy O, Montoro FM, Neau JP, Richard S, Rosolacci T, Sibon I, Sablot D, Timsit S, Zuber M, Cordonnier C, and Bordet R
- Subjects
- Combined Modality Therapy, Disability Evaluation, France, Humans, Leadership, Neurologic Examination, Randomized Controlled Trials as Topic, Recovery of Function, Stroke diagnosis, Stroke physiopathology, Stroke psychology, Time Factors, Treatment Outcome, Caregivers psychology, Nurse's Role, Patient Care Team, Patient Education as Topic methods, Secondary Prevention methods, Stroke therapy, Stroke Rehabilitation methods
- Abstract
Background: Setting up a follow-up secondary prevention program after stroke is difficult due to motor and cognitive impairment, but necessary to prevent recurrence and improve patients' quality of life. To involve a referent nurse and a caregiver from the patient's social circle in nurse-led multimodal and long-term management of risk factors after stroke could be an advantage due to their easier access to the patient and family. The aim of this study is to compare the benefit of optimized follow up by nursing personnel from the vascular neurology department including therapeutic follow up, and an interventional program directed to the patient and a caregiving member of their social circle, as compared with typical follow up in order to develop a specific follow-up program of secondary prevention of stroke., Methods/design: The design is a randomized, controlled, clinical trial conducted in the French Stroke Unit of the Strokavenir network. In total, 410 patients will be recruited and randomized in optimized follow up or usual follow up for 2 years. In both group, patients will be seen by a neurologist at 6, 12 and 24 months. The optimized follow up will include follow up by a nurse from the vascular neurology department, including therapeutic follow up, and a training program on secondary prevention directed to the patient and a caregiving member of their social circle. After discharge, a monthly telephone interview, in the first year and every 3 months in the second year, will be performed by the nurse. At 6, 12 and 24 month, the nurse will give the patient and caregiver another training session. Usual follow up is only done by the patient's general practitioner, after classical information on secondary prevention of risk factors during hospitalization. The primary outcome measure is blood pressure measured after the first year of follow up. Blood pressure will be measured by nursing personnel who do not know the group into which the patient has been randomized. Secondary endpoints are associated mortality, morbidity, recurrence, drug side-effects and medico-economic analysis., Discussion: The result of this trial is expected to provide the benefit of a nurse-led optimized multimodal and long-term interventional program for management of risk factors after stroke, personalizing the role of the nurse and including the patient's caregiver., Trial Registration: ClinicalTrials.gov, NCT 02132364. Registered on 7 May 2014. EUDRACT, A 00473-40.
- Published
- 2018
- Full Text
- View/download PDF
50. Target Door-to-Needle Time for Tissue Plasminogen Activator Treatment with Magnetic Resonance Imaging Screening Can Be Reduced to 45 min.
- Author
-
Sablot D, Ion I, Khlifa K, Farouil G, Leibinger F, Gaillard N, Laverdure A, Bensalah ZM, Mas J, Fadat B, Smadja P, Ferraro-Allou A, Bonnec JM, Olivier N, Dutray A, Tardieu M, Dumitrana A, Guibal A, Jurici S, Bertrand JL, Allou T, Arquizan C, and Bonafe A
- Subjects
- Aged, Aged, 80 and over, Disability Evaluation, Female, France, Hospital Mortality, Humans, Infusions, Intravenous, Intracranial Hemorrhages chemically induced, Male, Middle Aged, Patient Admission, Predictive Value of Tests, Quality Improvement, Quality Indicators, Health Care, Recovery of Function, Stroke mortality, Stroke physiopathology, Thrombolytic Therapy adverse effects, Thrombolytic Therapy mortality, Time Factors, Tissue Plasminogen Activator adverse effects, Treatment Outcome, Workflow, Fibrinolytic Agents administration & dosage, Magnetic Resonance Imaging, Stroke diagnostic imaging, Stroke drug therapy, Thrombolytic Therapy methods, Time-to-Treatment, Tissue Plasminogen Activator administration & dosage
- Abstract
Objective: The purpose of this study was to demonstrate that the median door-to-needle (DTN) time for intravenous tissue plasminogen activator (tPA) treatment can be reduced to 45 min in a primary stroke centre with MRI-based screening for acute ischaemic stroke (AIS)., Methods: From February 2015 to February 2017, the stroke unit of Perpignan general hospital, France, implemented a quality-improvement (QI) process. During this period, patients who received tPA within 4.5 h after AIS onset were included in the QI cohort. Their clinical characteristics and timing metrics were compared each semester and also with those of 135 consecutive patients with AIS treated by tPA during the 1-year pre-QI period (pre-QI cohort)., Results: In the QI cohort, 274 patients (92.5%) underwent MRI screening. While the demographic and baseline characteristics were not significantly different between cohorts, the median DTN time was significantly lower in the QI than in the pre-QI cohort (52 vs. 84 min; p < 0.00001). Within the QI cohort, the median DTN time for each semester decreased from 65 to 44 min (p < 0.00001) and the proportion of treated patients with a DTN time ≤45 min increased from 25 to 58.9% (p < 0.0001). Overall, DTN time improvement was associated with a better outcome at 3 months (patients with a modified Rankin Scale score between 0 and 2: 61.8% in the QI vs. 39.3% in the pre-QI cohort; p < 0.0001)., Conclusions: A QI process can reduce the DTN within 45 min with MRI as a screening tool., (© 2018 S. Karger AG, Basel.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.